The QualityStocks Daily Tuesday, July 28th, 2020

Today's Top 3 Investment Newsletters

MarketClub Analysis (KODK) +203.05%

QualityStocks (BSRC) +78.79%

MarketBeat (VCRA) +34.02%

The QualityStocks Daily Stock List

Bionano Genomics, Inc. (BNGO)

NetworkNewsWire, PennyStocks, RTTNews, NewsDaemon, Marketing Sentinel, Spotlight Growth, News Quantified, Fosters Research, Simply Wall St, iwatchmarkets, FX Street, Seeking Alpha, Morningstar, Invest Chronicle, Barchart, Finbox, Nasdaq, Market Chameleon, MarketBeat, GlobeNewswire, last10k, Invest Million, Zacks, Proactive Investors, Investors Observer, News RTS, InvestorsHub, Street Insider, Market Screener, Wallet Investor, StocksRegister, YCharts, Investing.com, Finviz, ChartMill, TMXmoney, MacroTrends, Stockhouse, Stocktwits, MarketWatch, Investcom.com, DBT News, GuruFocus, NasdaqNewsFeed, and PR Newswire reported earlier on Bionano Genomics, Inc. (BNGO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

A genome analysis company, Bionano Genomics, Inc. provides tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing. The Company’s Saphyr system is a platform for ultra-sensitive and ultra-specific structural variation detection. The platform enables researchers and clinicians to speed up the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics.

Established in 2003, Bionano Genomics is based in San Diego, California. Its shares trade on the NasdaqGS. The Company was previously known as BioNano Genomics, Inc. It changed its name to Bionano Genomics, Inc. in July of 2018. The Saphyr system consists of an instrument, chip consumables, reagents, and also a set of data analysis tools, and genome analysis services. This is to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs.

Saphyr detects all CNVs, chromosomal abnormalities, and structural variants. It consolidates the traditional cytogenetic assays into one single workflow. Saphyr can detect all structural variant kinds at high sensitivities. This includes those present at low allele fractions in heterogenous cancer samples, in an unbiased genome-wide way. This modern tool has revolutionized cytogenomics through showing a 100 percent concordance to traditional methods – array CGH, karyotyping, as well as FISH.

Last week, Bionano Genomics announced that a study published in the journal Nature used the Company’s genome imaging technology to establish one of the largest and most structurally accurate sets of genome data for a cohort of affected children and their parents in a study of the most common genomic deletion syndrome, called 22q11.2 Deletion Syndrome (22q11.2DS) or DiGeorge Syndrome. The 22q11.2 Deletion Syndrome (22q11.2DS) is a congenital malformation disorder. It is the most frequent microdeletion syndrome in humans.

Mr. Erik Holmlin, PhD, Chief Executive Officer of Bionano Genomics, said, “The 22q11.2DS study published in Nature demonstrates once again that Bionano’s genome imaging technology is capable of resolving the structure and orientation of the most complex regions of the genome. The single DNA molecules imaged by Saphyr are up to millions of base pairs in length, providing an unambiguous view of the genome that we believe cannot be obtained with short-read or long-read sequencing technologies.”

Bionano Genomics, Inc. (BNGO), closed Tuesday's trading session at $0.825, up 1.4635%, on 23,340,652 volume with 26,490 trades. The average volume for the last 3 months is 20,847,609 and the stock's 52-week low/high is $0.25/$4.6999998.

chart

BioSyent, Inc. (BIOYF)

Value Forum, Stock News Now, Seeking Alpha, Stockhouse, Market Screener, Nasdaq, GuruFocus, YCharts, TradingView, 4-Traders, OTC Markets, Investing.com, TMXmoney, Dividend Investor, Central Charts, Simply Wall St, moneyhub.net, GlobeNewswire, Barchart, Stockscores, Investors Hangout, Morningstar, and Wallet Investor reported beforehand on BioSyent, Inc. (BIOYF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

BioSyent, Inc. is a specialty pharmaceutical company listed on the OTC Markets. Through its subsidiaries, it sources, acquires, or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. The Company formerly went by the name Hedley Technologies, Inc. It changed its corporate name to BioSyent, Inc. in June of 2006 to reflect its forward emphasis on the pharmaceutical market. BioSyent has its head office in Mississauga, Ontario.

BioSyent supports the healthcare professionals that treat patients by marketing its products via its community, hospital, and global business units. The Company continues to search for products to in-license or acquire that are unique and occupy a niche in the market; provide novel technological or therapeutic advantages to patients and healthcare professionals; and are backed by strong partners who hold defendable intellectual property (IP) rights.

BioSyent recently announced that for the fifth consecutive year, FeraMAX® was named the #1 recommended iron supplement brand in a national survey of Canadian pharmacists and physicians. FeraMAX® 150 is an oral iron supplement indicated for the prevention and treatment of iron deficiency anaemia. The 2020 Survey on OTC Counselling & Recommendations was conducted by Ensemble IQ, Research, Insights and Innovation team and the following publications and websites: Pharmacy Practice + Business, The Medical Post, Profession Santé, CanadianHealthcareNetwork.ca, and ProfessionSanté.ca.

BioSyent owns a legacy business that manufactures and markets Protect-It®. This is a bio-friendly non-toxic product used in agriculture. The business is operated by wholly-owned subsidiary Hedley Technologies Ltd. Protect-It® is a non-chemical, food-safe grain insecticide. BioSyent’s other products include the Aguettant System® for pre-filled syringes (PFS); Cathejell®; CYSVIEW® Blue-Light Cystoscopy (BLC); Proktis-M® (sodium hyaluronate) rectal suppository; and RepaGyn® (sodium hyaluronate) vaginal suppository.

In late May, BioSyent released a summary of its financial results for the three months ended March 31, 2020. Selected highlights include Q1 2020 Net Revenues of $6,062,846 increasing by 35 percent in comparison to Q1 2019. Q1 2020 Canadian Pharmaceutical Net Revenues of $5,955,561 increased by 39 percent versus Q1 2019.

Q1 2020 EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of $1,997,987 increased by 66 percent in comparison to Q1 2019. Q1 2020 Net Income After Taxes (NIAT) of $1,451,518 increased by 48 percent versus Q1 2019.

BioSyent, Inc. (BIOYF), closed Tuesday's trading session at $4.6073, even for the day, on 30,300 volume. The average volume for the last 3 months is 4,523 and the stock's 52-week low/high is $2.15050005/$5.50.

chart
n

Body and Mind, Inc. (BMMJ)

MicroSmallCap, Whale Wisdom, New Cannabis Ventures, Midas Letter, Dividend Investor, Wallmine, InvestorsHub, Penny Stock Tweets, Insider Financial, PotStockNews, technical420, Investor Ideas, Market News Updates, Fitmig, MJ Global Report, Market Screener, Simply Wall St, Stockhouse, Wallet Investor, GuruFocus, Investors Observer, Trading View, StockTreats, and Market Wire News reported beforehand on Body and Mind, Inc. (BMMJ), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Body and Mind, Inc. invests in high quality medical and recreational cannabis cultivation, production, and retail. The Company’s wholly-owned Nevada subsidiary was awarded one of the first medical marijuana cultivation licences. In addition, Body and Mind holds cultivation and production licenses. Body and Mind (BaM) products include dried flower, edibles, topicals, extracts, as well as GPEN Gio cartridges.

Established in 1998, Body and Mind is based in Vancouver, British Columbia. The Company lists on the OTC Markets Group’s OTCQB. The Company previously went by the name Deploy Technologies, Inc. It changed its name to Body and Mind, Inc. in November of 2017. Nevada Medical Group LLC (NMG Nevada) is a wholly-owned subsidiary of Body and Mind.

The Company has collected, for many years’, elite cannabis plants from around the world. Through carefully crossbreeding these plants, the Company has developed strains that give what Body and Mind states are the perfect balance of body and mind benefits. Its cannabis plants are grown with hands-on care in small batches. Moreover, Body and Mind never uses synthetic pesticides. It offers a variety of strains, available in flower, vapes, pre-rolls, and concentrates.

Body and Mind cannabis strains have won multiple awards. These include the 2019 Las Vegas Weekly Bud Bracket, Las Vegas Hempfest Cup 2016, High Times Top Ten, the NorCal Secret Cup, and the Emerald Cup.

In 2019, Body and Mind announced expansion into Arkansas with in-State partner, Comprehensive Care Group LLC (CCG). Medical marijuana dispensaries in Arkansas are licensed for retail sales and cultivation of up to 50 plants within the same facility.

Body and Mind has commenced manufacturing in California via the Body and Mind California subsidiary NMG Cathedral City (NMG). The Cathedral City facility has been producing THC (Tetrahydrocannabinol) distillate in bulk form since June of 2018. This facility is for manufacturing popular Body and Mind products. This includes oils, wax, live resin, ambrosia, and edibles. Body and Mind continues to expand operations in Nevada, California, Arkansas, as well as Ohio.

This month, Body and Mind announced that it has started a License Agreement for directing manufacturing and distribution in California with Sense Distribution, doing business under the brand name Shoogies, which is a specialty cannabis brand offering THC (Tetrahydrocannabinol) infused all-natural sweeteners.

Mr. Michael Mills, Chief Executive Officer of Body and Mind, said, "Our California retail operations continue to grow after our successful San Diego grand opening and we are excited to see improvements in the Nevada market with increased tourism in Las Vegas. We are proud to be selected by Sense for a new licensing agreement as we continue to expand our manufacturing and distribution operations as a debt-free multi-state operator.”

Body and Mind, Inc. (BMMJ), closed Tuesday's trading session at $0.265, up 0.378788%, on 40,518 volume with 26 trades. The average volume for the last 3 months is 64,196 and the stock's 52-week low/high is $0.150000005/$1.17999994.

chart

ContraFect Corporation (CFRX)

Zacks, Morningstar, BioPharmCatalyst, The Stock Market Watch, YCharts, Proactive Investors, Stockwatch, ETF.com, InvestorsHub, News RTS, Invest Million, Stocktwits, GlobeNewswire, Simply Wall St, Nasdaq, Stocknews, The Baxter Report, ETF Channel, Seeking Alpha, TMXmoney, GlobeNewswire, NasdaqTrader, Street Insider, Investing.com, Market Screener, Stockhouse, and Insider Tracking reported beforehand on ContraFect Corporation (CFRX), and today we report on the Company, here at the QualityStocks Daily Newsletter.

A clinical-stage biotechnology enterprise, ContraFect Corporation concentrates on discovering and developing direct lytic agents (DLAs), including lysins and amurin peptides, for the treatment of life-threatening infectious diseases. It believes that the properties of its lysins and amurin peptides will make them suitable for targeting antibiotic-resistant organisms, including methicillin-resistant Staph aureus (MRSA) and P. aeruginosa, which can cause serious infections such as bacteremia, pneumonia, and osteomyelitis. Esatblished in 2008, ContraFect is based in Yonkers, New York, and the Company lists on the NasdaqCM.

Lysins are a new class of DLAs that are recombinantly produced antimicrobial proteins with a novel mechanism of action associated with the fast killing of target bacteria, eradication of biofilms, and synergy with conventional antibiotics. Amurin peptides are a novel class of DLAs that exhibit broad-spectrum activity against a wide assortment of antibiotic-resistant Gram-negative pathogens.

ContraFect has completed a Phase 2 clinical trial for the treatment of Staph aureus bacteremia, including endocarditis, with its lead lysin candidate, exebacase, which is the first lysin to enter clinical studies in the U.S. Exebacase (CF-301) is a lysin with potent activity against Staphylococcus aureus (Staph aureus).

Exebacase has the potential to be the first-in-class of a new treatment for patients with Staph aureus bacteremia. Exebacase, now undergoing study in a pivotal Phase 3 clinical study, was granted Breakthrough Therapy designation by the Food and Drug Administration (FDA) for the treatment of MRSA bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to standard-of-care (SOC) anti-staphylococcal antibiotics in adult patients.

The focus of ContraFect’s research and discovery efforts is on identifying and engineering lysins that selectively kill specific species of Gram-negative bacteria. Additionally, concerning amurins, ContraFect has discovered a new class of phage-encoded lytic antimicrobial peptides that have potent in vitro activity across a wide spectrum of resistant Gram-negative pathogens. These include species that are part of the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species).

In June, ContraFect announced the publication of the exebacase Phase 2 study results in the July 1, 2020 issue of the Journal of Clinical Investigation. The study results established clinical proof-of-concept for exebacase and informed the design of the continuing Phase 3 DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial) study of exebacase for the treatment of patients with life-threatening Staph aureus bloodstream infections (BSIs). This includes right-sided endocarditis.

Last week, ContraFect announced that CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator), an international non-profit partnership committed to hastening antibacterial research and development (R&D), is awarding ContraFect up to $18.9 million in additional non-dilutive capital to progress its second product candidate, CF-370, an engineered lysin targeting Pseudomonas aeruginosa (P. aeruginosa), in IND-enabling activities toward future Phase 1 clinical trials.

The award provides initial funding of $4.9 million. The Company could receive additional funding if certain project milestones are met. Any funding beyond the initial $4.9 million is at the sole discretion of CARB-X and subject to available funds.

ContraFect Corporation (CFRX), closed Tuesday's trading session at $5.74, off by 0.863558%, on 396,950 volume with 4,007 trades. The average volume for the last 3 months is 379,266 and the stock's 52-week low/high is $2.69300007/$13.3990001.

chart

Fearless Films, Inc. (FERL)

Emerging Growth, Awesome Penny Stocks, The Stock Market Watch, FX Empire, Street Insider, TradingView, Morningstar, InvestorsHub, Simply Wall St, Stockhouse, Dividend Investor, Stockopedia, Stockwatch, Investors Observer, Barchart, Business Insider, YCharts, Ask Finny, Dividend.com, Baystreet.ca, GuruFocus, TheOnside.com, OTC Markets, docoh, PR Newswire, PitchBook, Accesswire, Nasdaq, Stockprice, TipRanks, Wallet Investor, and Seeking Alpha reported previously on Fearless Films, Inc. (FERL), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Fearless Films, Inc. is an independent full-service production Company listed on the OTCQB tier of the OTC Market. Award-winning actor/producer Mr. Victor Altomare along with award-winning writer and director Mr. Goran Kalezic founded the Company. The Company offers its services to directors and writers, and also for post-production and distribution/fulfillment. Fearless Films has its corporate headquarters in Concord, Ontario.

The Company’s service scope specializes in short film and feature film production in addition to script writing, copywriting, fulfillment, and distribution. Fearless Films has the ability to realize any task associated with video production. Since the Company’s inception, Fearless Films has been on the map as a foremost independent producer. It has won accolades at most major film festivals. Fearless Films has a reputation for having a well-honed eye for emerging talent.

Fearless Films is operating in the worldwide video streaming market. The expectation is that this market will reach a value of USD $124.57 billion by 2025 according to Grand View Research. The Company has an experienced and successful Management Team helping to further expand its product offerings.

At the end of June, Fearless Films announced that it closed a non-brokered private placement offering of up to 6,666,668 shares priced at $0.15 per common share for gross proceeds of $1,000,000 USD. The Offering is priced at a premium of 22 percent to Fearless Films’ 20-day volume-weighted average trading price. The proceeds of this Offering will be used to support the operations of the Company. This includes brand building and film production. Fearless Films plans to commence production on its next film during this calendar year.

Earlier this month, Fearless Films announced that it will be applying to list its share on a stock exchange in Canada. This is in addition to its current listing on the OTCQB market. Fearless Films decided to take this step to access a broader pool of capital and to increase liquidity options for its shareholders.

Today, Fearless Films announced that it completed an agreement to acquire “In the Lair”, another major addition to its growing library of media titles. “In the Lair” was written and directed by Mr. Goran Kalezic.

The movie was exhibited at the Venice Film Festival in an abbreviated form as "The Calling". Mr. Kalezic is a writer and director, known for The Great Chameleon (2012), The Bartender (2005) – voted audience favourite at Indyfest, Bag the Wolf (2000), and Only Minutes (1998). In addition, he is the author of Dostoevsky's Anarchists: A Screenplay Adaptation of Dostoevsky's Demons (2018).

Fearless Films, Inc. (FERL), closed Tuesday's trading session at $0.0895, off by 4.2781%, on 1,495,191 volume with 349 trades. The average volume for the last 3 months is 818,882 and the stock's 52-week low/high is $0.0153/$0.699999988.

chart

Heat Biologics, Inc. (HTBX)

Market Chameleon, BioPharmaJournal, Finbox, BioPharmCatalyst, Stocktwits, DBT News, Finviz, ChartMill, ETF.com, Invest Chronicle, Currency.com, TMXmoney, TradingView, Investing.com, Proactive Investors, Morningstar, Barchart, NewsDaemon, YCharts, InvestorsHub, Simply Wall St, Stockhouse, MacroTrends, Market Screener, Investors Observer, Seeking Alpha, Stocknews, Zacks, Business Insider, and Nasdaq reported previously on Heat Biologics, Inc. (HTBX), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Heat Biologics, Inc. is a clinical-stage biopharmaceutical company listed on the NasdaqGS. It centers on developing first-in-class therapies to modulate the immune system. This includes manifold oncology product candidates and a novel COVID-19 vaccine product candidate. The Company has a proprietary gp96 platform to activate immune responses against pathogenic or cancer antigens. Heat Biologics has its corporate office in Morrisville, North Carolina. It also has operations in San Antonio, Texas.

The Company has numerous product candidates in development taking advantage of the gp96 platform. These include HS-110, which has completed enrollment in its Phase 2 trial; HS-130 in Phase 1; and also a COVID-19 vaccine program in preclinical development.

Furthermore, Heat Biologics is developing a pipeline of proprietary immunomodulatory antibodies. This includes PTX-35, which is enrolling in a Phase 1 trial.

Last month, Heat Biologics announced that the first patient was treated in the Company's first-in-human Phase 1 clinical trial evaluating PTX-35. This is the first antibody product candidate developed by Heat Biologics' Pelican Therapeutics subsidiary. The trial is supported by a $15.2 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT).

The expectation is that this first-in-human study will enroll up to 30 patients with advanced solid tumors refractory to standard of care. Eligible patients will be enrolled to receive PTX-35 every two weeks until disease progression.

Escalating dose levels of PTX-35 will be explored until optimal immunological dose or maximum tolerated dose is established. The goals of this study include safety evaluation, determination of the recommended Phase 2 dose, and exploratory analyses of clinical benefit and immunological effect of PTX-35.

PTX-35 is a novel, potential first-in-class antibody T-cell co-stimulator. It targets TNFRSF25 (death receptor 3), a receptor that is preferentially expressed by antigen-experienced T cells. TNFRSF25 agonism leads to activation of antigen-experienced memory CD8+ T cells that are instrumental for tumor destruction.

Heat Biologics, Inc. (HTBX), closed Tuesday's trading session at $2.07, off by 12.2881%, on 45,287,642 volume with 71,830 trades. The average volume for the last 3 months is 26,585,847 and the stock's 52-week low/high is $0.194999992/$4.30000019.

chart

Teras Resources, Inc. (TRARF)

Stockscores, 24hgold, TalkMarkets, Wallet Investor, Junior Mining Network, Financial Trends, Accesswire, Ask Finny, Dividend Investor, Seeking Alpha, PR Newswire, Market Screener, Mining Capital, Canadian Mining Report, Morningstar, Newsfilecorp, Stockhouse, Investing News, Proactive Investors, Stockwatch, 4-Traders, Investors Hangout, TradingView, moneyhub.net, Barchart, and GuruFocus reported earlier on Teras Resources, Inc. (TRARF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Teras Resources, Inc. centers on implementing sound scientific practices in exploring and developing high-quality gold and base metal properties in North America. It is focusing on developing its flagship Cahuilla project in Imperial County, California. Cahuilla is in an ideal location for mining year-round with premier infrastructure. The Company formerly went by the name Profile Resources, Inc. It changed its name to Teras Resources, Inc. in September of 2006. Teras Resources is based in Calgary, Alberta.

The Cahuilla project covers an area of at least 3 km by 1.5 km. The Company believes that the Cahuilla project has the potential to develop into a mining operation comprising altered and mineralized sedimentary host rocks with manifold sheeted high-grade sheeted quartz veins.

Teras Resources filed a NI 43-101 technical report with an indicated resource of 1.0 million ounces of gold and 11.9 million ounces of silver on the Cahuilla project (70 million tons at an average grade of 0.015 ounces per ton gold and 0.17 ounces per ton silver with a cut-off of 0.008 ounces per ton gold) and inferred class of 10 million tons grading 0.011 opt gold and 0.10 opt silver. Gold equivalent ounces are 1.2 million ounces in indicated class and 130,000 ounces in inferred class using a ratio of 55 silver ounces to 1 gold ounce.

Tera owns or controls roughly 1800 acres of prospective land. This resource only occupies 143 acres. This leaves more than 90 percent of the project available for growth. Numerous historic drill holes that cover the remaining project area host strongly anomalous precious metal mineralization.

In addition, the Company owns a 100 percent interest in the Corral Canyon Gold Project in Churchill County, Nevada; and a 100 percent interest in the unpatented claims of the Gold Point Property in Sierra County, California. Teras also has its Sunny Slope gold mine – a high-grade, quartz-gold vein system hosted in metamorphosed sedimentary, volcanic, and intrusive rocks. This property is in Mineral County, Nevada. Teras Resources owns 100 percent in the unpatented claims that have no underlying royalties.

Moreover, Teras has its Watseka Mill Site and Mine Site. It is in the Rochester Mining District and is positioned about nine miles northwest of Twin Bridges, Madison County, Montana, on the east slope of the Continental Divide. Furthermore, Teras Resources has its Superstition Mountain Gold Property in Imperial County, California, approximately 20 miles northwest of the town of El Centro. The Company also has its Golden Jubilee property. This property comprises 22 mineral lode claims (about 227 acres) situated in Granite County, Montana.

In June, Teras Resources announced that over the past several months, the Company has engaged a number of consultants to examine the database of Teras’ flagship "Cahuilla Project" for advice and guidance concerning future drill programs to increase the current grade and global resource of the project. Teras said the study was comprehensive. It led to optimistic findings regarding delineating the high grade sheeted veins and locating new high priority drill targets.

The Company has now engaged two groups to work with the revised dataset for internal re-modelling of the existing 2012 NI 43-101 resource model. This newly updated information will assist Teras in its discussions internally and externally with potential interested parties.

Teras Resources, Inc. (TRARF), closed Tuesday's trading session at $0.0597, up 8.5455%, on 10,100 volume with 3 trades. The average volume for the last 3 months is 9,457 and the stock's 52-week low/high is $0.0239/$0.059700001.

chart

Spring Bank Pharmaceuticals, Inc. (SBPH)

Zacks, BioPharmCatalyst, StockNews, Stock Twits, US Post News, TipRanks, The Online Investor, MacroTrends, Central Charts, ETF.com, Simply Wall St, Stockhouse, Investors Observer, Morningstar, Market Chameleon, Stockwatch, YCharts, and Investing.com reported earlier on Spring Bank Pharmaceuticals, Inc. (SBPH), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company listed on the NasdaqCM. It is developing novel therapeutics for the treatment of viral infections, inflammatory diseases, as well as certain cancers. Spring Bank’s lead product candidate is inarigivir. The Company previously went by the name Spring Bank Technologies, Inc. It changed its name to Spring Bank Pharmaceuticals, Inc. in May of 2008. Established in 2002, Spring Bank Pharmaceuticals has its corporate headquarters in Hopkinton, Massachusetts.

In essence, the Company engages in the discovery and development of a novel class of therapeutics utilizing its proprietary small molecule nucleotide platform. It designs its compounds to selectively target and modulate the activity of specific proteins implicated in different disease states.

Spring Bank Pharmaceuticals’ inarigivir is undergoing development for the treatment of chronic hepatitis B virus (HBV). The design of inarigivir is to activate within hepatic cells retinoic acid-inducible gene 1 (RIG-I) that has been shown to inhibit HBV viral replication and induce the intracellular interferon signaling pathways for antiviral defense.

Inarigivir is undergoing development as a simple, safe, and also selective oral immunomodulator for inclusion in a combinatorial treatment of hepatitis B. In addition, Spring Bank is developing its lead STING agonist product candidate, SB 11285. This is an immunotherapeutic agent for the treatment of selected cancers.

Regarding the Company’s science, its proprietary small molecule nucleic acid hybrids (SMNH) chemistry platform produces a class of compounds designed to selectively target and modulate the activity of specific proteins implicated in different disease states. The design of its SMNH compounds are to resemble naturally occurring nucleotides and nucleic acids in the body. They act directly on target proteins. As a result, they can be used to upregulate or downregulate the activity of disease-related proteins.

Recently, Spring Bank Pharmaceuticals announced that it stopped dosing and enrolling patients in its Phase 2b CATALYST trials that are examining the use of inarigivir soproxil 400mg for the treatment of chronic hepatitis B virus (HBV). Furthermore, Spring Bank has stopped dosing and enrollment in all other studies of inarigivir in subjects with chronic HBV.

Mr. Martin Driscoll, President and Chief Executive Officer of Spring Bank Pharmaceuticals, said, “We stopped dosing and enrolling patients out of an abundance of caution based on laboratory data from virally-suppressed patients in the CATALYST 2 trial. We are certainly disappointed to stop our current Phase 2 inarigivir trials, but ensuring patient safety and care is of paramount importance to us. Working with the members of our Data Safety Monitoring Board, clinical trial investigators and external experts, we will review all of the information available to us from the CATALYST 2 trial and all other inarigivir trials at the 400mg dose to determine the appropriate path forward for these trials.”

Spring Bank Pharmaceuticals, Inc. (SBPH), closed Tuesday's trading session at $2.57, up 41.9889%, on 2,451,657 volume with 7,415 trades. The average volume for the last 3 months is 98,569 and the stock's 52-week low/high is $0.800000011/$4.98999977.

chart

Bespoke Extracts, Inc. (BSPK)

Simply Wall St, Stockopedia, InvestorsHub, Wallmine, Stockhouse, Ventureline, GuruFocus, Investors Hangout, Barchart, Wallet Investor, Infront Analytics, YCharts, Market Screener, Morningstar, Market Exclusive, Marketwired, Insider Financial, and MarketWatch reported earlier on Bespoke Extracts, Inc. (BSPK), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Bespoke Extracts, Inc. is a producer of high quality, flavorful, hemp-derived cannabidiol (CBD) extract products. The Company established in early 2017 to introduce a proprietary line of premium quality, all-natural CBD products in the form of tinctures and capsules for the nutraceutical and veterinary markets. Bespoke Extracts is headquartered in Sunny Isles Beach, Florida. The Company’s shares trade on the OTC Markets Group’s OTCQB.

The Company’s products are marketed as dietary supplements and distributed through the Company’s direct-to-consumers e-commerce store. Bespoke’s products are produced using pure, all natural, zero-THC phytocannabinoid-rich (PCR) hemp-derived CBD. CBD is non-psychoactive. CBD (cannabidiol) is one of over 85 cannabinoids found in cannabis. CBD is present in more significant quantities in hemp than it is marijuana.

Bespoke Extracts’ mission is to become one of the world’s most trusted sources for premium quality, all-natural, USA-grown, hemp-derived cannabidiol (CBD) products for the nutraceutical and veterinary markets. The Company strives to use only vegan, Fair Trade Certified, and organic ingredients with fast acting benefits for anyone looking for an alternative remedy. Bespoke’s farmers have been innovators in hemp agriculture, farming practices, agrotech, as well as production for generations. Bespoke’s hemp is stable, high in CBD, low in THC, and resistant to pathogens and pests.

The Company’s products include Sport Lemon Lime Tincture – THC Free 1500MG; CBD Manuka Honey Tincture; and CBD Bacon Flavored Pet Tincture. Moreover, products include CBD Softgel Capsules; CBD Pain Relief Cream; and CBD Isolate Powder.

Bespoke Extracts announced this past November that its Board of Directors appointed Niquana (Nikki) Noel as President and Chief Executive Officer (CEO), effective immediately. Serving Bespoke as its Operations Manager, Noel assumed day-to-day leadership of the Company and joined its Board of Directors. Noel has spent close to two decades working with privately-held and publicly-traded micro and small cap companies.

Bespoke Extracts, Inc. (BSPK), closed Tuesday's trading session at $0.016, up 48.1481%, on 162,022 volume with 17 trades. The average volume for the last 3 months is 49,222 and the stock's 52-week low/high is $0.006/$0.039999999.

chart

Rebel Group, Inc. (REBL)

OTC Markets, Market Screener, InvestorsHub, MarketWatch, Investing, 4-Traders, The Street, Stockhouse, GuruFocus, Simply Wall St, Awesome Penny Stocks, Barchart, Wallet Investor, Ceo.ca, Penny Stock Hub, Morningstar, and YCharts reported earlier on Rebel Group, Inc. (REBL), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Rebel Group, Inc., by way of its subsidiaries, organizes, promotes, and hosts mixed martial arts (MMA) events in China and Singapore. The Company’s focus is on organizing, promoting and hosting MMA events that attract talented fighters from around the world. An MMA entertainment company, Rebel Group has its corporate headquarters in Singapore. Established in May 2013, the Company is a subsidiary of Total Glory International Limited. Rebel Group lists on the OTCQB.

The Company operates under the Rebel Fighting Championship (Rebel FC) brand. Rebel Group carries out its operations through managing events, fighters, ticket sales, sponsorships, and pay-per-view purchases. The Company produces and distributes its events via the internet and social media. It works to sell the rights to distribute videos of its MMA events to television stations.

Rebel FC hosts all its events with MMA stars from around the world. The Company’s aim is to bring martial arts back to its birthplace – China. Through bringing the biggest fights to China, REBEL FC provides a platform for Chinese MMA fighters to excel on the world MMA stage by pitting them against the best international fighters.

Rebel Group creates international events featuring a line-up of legendary worldwide stars. These include Miguel Torres of the U.S and Takeshi “Lion” Inoue of Japan, as well as MMA champions from China. These include Liu Wenbo, Tang Kai, Wang Sai, Ning Guangyou and China’s No.1 ranked Bantamweight fighter and Rebel FC Champion, Ayideng Jumayi.

Rebel FC's long-term strategy is to develop the full potential of MMA in China. In addition, the Company’s strategy is to promote the sport as a lifestyle that mainstream audiences can embrace. Focusing on its intent to expand in China, REBEL FC hosted an event on September 7, 2018 at Beijing's National Olympic Stadium. It was titled REBEL FC 9 - Battle for the Kingdom, and it showcased the best MMA fighters China has to offer.

Rebel earlier announced the appointment of Mr. Benjamin Cher to REBEL FC’s Board of Directors as an Independent Director. Mr. Cher is an experienced professional with greater than 15 years of experience in banking, private equity, strategic planning and general management. He is the Founder and Chief Executive Officer of Aetius Capital, a Singapore-based private investment firm.

Rebel Group, Inc. (REBL), closed Tuesday's trading session at $2.30, up 152.7195%, on 1,000 volume with 1 trade. The average volume for the last 3 months is 46 and the stock's 52-week low/high is $0.490200012/$4.90000009.

chart

REGI U.S., Inc. (RGUS)

Zacks, Morningstar, Marketwired, The Street, MarketWatch, Barchart, OTC Markets and Stockhouse reported earlier on REGI U.S., Inc. (RGUS), and we report on the Company as well, here at the QualityStocks Daily Newsletter. 

REGI U.S., Inc., by way of its subsidiary, RadMax Technologies, Inc., engages in the design and development of axial vane-type rotary engines, known as the RadMax rotary technology, used in the design of engines, compressors, and pumps. RadMax Technologies is developing for commercialization numerous improved axial vane type rotary devices using its Patented RadMax™ Rotary Technology. REGI U.S. is based in Spokane, Washington. 

The RadMax™ Rotary Technology allows for leading-edge designs of lightweight and high efficiency engines, compressors, pumps, and other devices. One current prototype is The RadMax™ engine. It has only two unique moving parts, the vanes (up to 12) and the rotor, in comparison to the 40 moving parts in a basic four-cylinder piston engine. 

The Company’s aim is to license RadMax technology and/or participate in joint ventures (JVs) to manufacture RadMax products for specific applications. Market segments that could benefit from RadMax technology include (but are not limited to) transportation, aerospace, air conditioning and refrigeration, oil and gas production and distribution, power generation, marine, and military markets.

The Board of REGI U.S. and RadMax Technologies announced this past February that a provisional patent application was filed with the U.S. Patent and Trademark Office (USPTO) for the use of RadMax two-phase compressors and expanders to increase the efficiency of Rankine cycle steam electricity generation plants.

Also, in March, The Board of Directors of REGI U.S and RadMax Technologies announced that a provisional patent application was filed with the USPTO for the use of RadMax two-phase compressors and expanders to increase the efficiency of air conditioning and refrigeration cycles.

Earlier in July, The Board of Directors of Regi U.S. and its wholly-owned subsidiary, RadMax Technologies announced the achievement of a significant milestone in the development of the RadMax sliding axial vane gas expander. Ongoing development and testing of the gas expander prototypes have demonstrated overall efficiencies more than 70 percent, a major technical milestone.

The expectation is that future development and testing will further increase efficiencies, into the mid-80 percent range through using more advanced bearings, coatings, and other friction reducing technologies. In addition, testing has shown the device’s power curve as similar to other positive displacement engines and is characterized by a broad peak with high torque.

REGI U.S., Inc. (RGUS), closed Tuesday's trading session at $0.045, up 49.5017%, on 153,071 volume with 19 trades. The average volume for the last 3 months is 24,673 and the stock's 52-week low/high is $0.029999999/$0.119999997.

chart

BioSolar, Inc. (BSRC)

Stock Roach,  Stock Preacher,  Penny Stock Rumble,  Beacon Equity Research, TheLightningPicks, HoleinOneStocks.net, Investor News Source, StockHideout, TopPennyStockMovers, PennyTrader Publisher,  OTCPicks,  MicroStockProfit, and BioSolar Newsletter reported earlier on BioSolar, Inc. (BSRC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

BioSolar, Inc.  is developing  an inventive technology to increase the storage capacity, reduce the cost, and extend the life of lithium-ion batteries. The Company initially focused its development effort on high capacity cathode materials since most of contemporary Li-ion batteries are "cathode limited." With the objective of creating  BioSolar’s  next generation super battery technology,  the Company is presently investigating high capacity anode materials.  BioSolar has its corporate headquarters in Santa Clarita, California.

BioSolar has its BioBackSheet®.  The Company is the leading commercial provider of bio-based solar panel backsheets. A backsheet is a required insulating film in all solar photovoltaic panels. Its primary purpose is to protect the solar panel components, specifically the solar cells and wires.  The Company’s BioBackSheet® is the only commercially available Underwriters Laboratory (UL) certified bio-based backsheet. 

The Company is developing BioSolar supercapacitors. This is technology for lessening the cost of storing the energy of the sun.  BioSolar co-owns the patent-application for this supercapacitor technology with the University of California at Santa Barbara (UCSB). The Company is funding a sponsored research program to advance its development.  

  Through integrating BioSolar supercapacitors as the high power front-end to battery banks, with fewer battery banks than would usually be required, daytime solar energy can be rapidly  and cost-effectively stored for night-time use at a significantly lower cost. The  technology will enable solar energy systems users to decrease their dependence or go completely off the electric utility power grid.  

  BioSolar’s management believes that use of its silicon-metal (Si-M) anode materials, currently under development, can help reduce the cost of lithium-ion batteries. The expectation is that the Company’s Si-M anode material will be much less expensive than that of the benchmark silicon-carbon anode material that is the key cost issue typically associated with battery technology. BioSolar’s belief is that its strategy of pursuing anode material advancements to support next-generation lithium-ion batteries can play an important role within the electric vehicle sector, and the broader energy storage technology industry.

In 2017, BioSolar successfully completed the laboratory phase of its silicon nanocomposite alloy anode material technology development. BioSolar (with data that suggests its technology can attain considerably higher capacity at decreased costs,) began the process of identifying potential strategic partners for commercial development of its proprietary battery technology.

In addition, BioSolar signed a Joint Development Agreement with Top Battery, a foremost lithium-ion battery manufacturer. Furthermore, BioSolar developed a proprietary additive technology. This technology has the potential to improve all kinds of silicon anode materials. This includes Si carbon composite, Si oxide type, as well as Si alloys.

Furthermore, the Company demonstrated that its additive technology exhibited substantial improvement in battery capacity and capacity retention when applied to Si anodes made from Si micro-particles, a form of raw silicon more cost effective than Si nano-particles.

BioSolar, Inc. (BSRC), closed Tuesday's trading session at $0.0177, up 78.7879%, on 45,308,583 volume with 1,124 trades. The average volume for the last 3 months is 10,481,827 and the stock's 52-week low/high is $0.002799999/$0.045000001.

chart

TransAKT Ltd. (TAKD)

OTC Markets, Stockhouse, Barchart, and The Street reported on TransAKT Ltd. (TAKD), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

TransAKT Ltd. is a manufacturer of highly unique agricultural equipment used to grow a broad array of vegetables and fruit employing simulated sunlight from LED lamps in an indoor proprietary hydroponic system. In addition, the Company is an international distributor of LED lighting products centered on serving the fastest developing market of commercial, hospitality, and outdoor lighting. OTCQB-listed, TransAKT is based in Hong Kong.

The Company’s commitment is to helping business owners protect the environment through superior energy efficiency - replacing current non-energy-efficient light sources with energy-efficient light sources. Additionally, TransAKT is focusing on eliminating the use of chemical fertilizers and pesticides utilizing the latest hydroponic agricultural technology and pure nutrients.

The nutrient solutions used in production with its hydroponic systems leave no heavy metal and chemical residues. TransAKT’s product line includes commercial production and home growing systems.

TransAKT’s wholly-owned subsidiary is Vegfab Agriculture Technology Co., Ltd. Vegfab was created in 2010 by a team of ecologically minded semiconductor specialists knowledgeable about LED materials.

Furthermore, TransAKT is looking for opportunities to develop a BIO-technology business in China. The Company says that the cordyceps business is one project with the greatest potential. It has engaged a team of approximately 10 experts in BIO technology engineering to develop an extended product mix. These products will debut in China in the next few years.

Vegfab’s product line includes systems for commercial production and a home growing system, which enables families to grow safe and clean fruit and vegetables in their homes. Vegfab products are the subject of numerous patents. These include ones for vertically wall-mounted LED lights, and ventilation systems for grow boxes.

Vegfab provides complete growing systems consisting of proprietary simulated sunlight LED boards; growing racks in diverse configurations for commercial and residential applications; environment control and plant nutrition control components; portable work tables and ladders; fruit and vegetable seeds and nutrition products; and vegetables.

Vegfab’s vegetable production factory in Yangmei City, Taiwan is the only mass production facility for vegetables in Taiwan. The facility utilizes innovative technology to produce exceptional yields from a very small space. Production is very efficient through the use of simulated sunlight from LED lamps, up to 85 percent automated.

TransAKT Ltd. (TAKD), closed Tuesday's trading session at $0.02, up 60.00%, on 4,228 volume with 2 trades. The average volume for the last 3 months is 4,406 and the stock's 52-week low/high is $0.0125/$0.029999999.

chart

Calmare Therapeutics, Inc. (CTTC)

OTCBB Journal, TaglichBrothers, and SmallCapVoice reported earlier on Calmare Therapeutics, Inc. (CTTC), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Calmare Therapeutics, Inc. (the Calmare Pain Mitigation Therapy™ company) researches, develops, and commercializes chronic, neuropathic pain, and wound affliction devices. Calmare devices sell commercially to medical practices internationally. In addition, they are found in U.S. military hospitals, clinics, and on installations through the Company’s General Services Administration (GSA) military contract (V797P-4300B). Calmare Therapeutics is headquartered in Fairfield, Connecticut.

Calmare’s medical devices provide a non-pharmacological (no drugs), non-addictive (no narcotics), and non-invasive (over the skin) solution to chronic pain sufferers in an outpatient treatment setting. The Company supplements its medical devices with a catalogue of private label neurostimulation and sensory electrodes.

The Company’s flagship medical device is the Calmare® Pain Therapy Device. This is the world's only non-invasive and non-addictive modality that can successfully treat chronic, neuropathic pain. Calmare Therapeutics holds a U.S. Food & Drug Administration (FDA) 510k clearance designation (K081255) on its flagship device. This grants it the exclusive right to sell, market, research, and develop the medical device in the United States.

Concerning CALMARE® Pain Therapy Treatment, the device is FDA-cleared for U.S. sales, U.S. patented, and patent pending in other countries, and medically certified in Europe. The Calmare® Pain Therapy Device treats oncologic and neuropathic pain through a biophysical rather than biochemical approach.

In January 2017, Calmare Therapeutics announced it was approved to list and supply four sensory and stimulation electrodes and the Calmare® Pain Therapy Device on the GSA Advantage!® web portal. GSA Advantage! is the online shopping and ordering system, which provides access to thousands of contractors and millions of supplies (products) and services.

Calmare Therapeutics has been a preferred vendor of the U.S. federal government (GSA#V797P-4300b) since 2010. Devices, consumables, as well as related hardware sell to U.S. military hospitals and clinics across the U.S. The Company sells its devices in Europe under CE-mark designation.

Calmare creates partnerships with its clients and customers to maximize their Intellectual Property (IP) assets, reduce time-to-market, and add to their profitability. The Company’s Technology Sourcing Service seeks technologies that fit with customer business goals and presents them as potential licensing or IP acquisition candidates.

Greater than 6,000 chronic pain patients have been successfully treated with Calmare Pain Mitigation Therapy™ since the initial Calmare chronic pain treatment was administered in 2007. Calmare Therapeutics has licensed more than 500 technologies to more than 400 individual organizations.

Calmare Therapeutics, Inc. (CTTC), closed Tuesday's trading session at $0.0955, up 50.3937%, on 500 volume with 1 trade. The average volume for the last 3 months is 7,049 and the stock's 52-week low/high is $0.0601/$0.197999998.

chart

The QualityStocks Company Corner

Deltec Bank & Trust Ltd.

The QualityStocks Daily Newsletter would like to spotlight Deltec Bank & Trust Ltd..

Deltec Bank & Trust moves beyond its core set of services to provide periodic and specialized research reports published for the benefit of its clients. A recent article discussing this reads, “As a leading financial hub for the global investment, finance and entrepreneur community, Deltec Bank & Trust offers specialized financial solutions and institutional expertise with the primary goal of creating opportunities for its clients to enhance their wealth. As part of its service offerings, the company recently released a special report (http://ibn.fm/7Ig6O) outlining details of the U.S. government’s $2.2 trillion Coronavirus Aid, Relief, and Economic Security (‘CARES’) stimulus package. The timely piece includes commentary concerning the potential effects to U.S. personal incomes should the unemployment insurance (‘UI’) benefits be allowed to expire at the end of the month without extension.” To view the full article, visit http://ibn.fm/62Dms.

Deltec Bank & Trust Ltd. is a leading financial hub for global investors, financiers and entrepreneurs. The private and corporate bank offers its clients a unique suite of bespoke financial solutions, institutional expertise and highly attentive service with an aim toward creating a network of opportunities to enhance client wealth. Deltec Bank & Trust Ltd. is the flagship company of the Deltec International Group, a diversified independent financial services group providing a range of financial services including fund administration, corporate advisory, merchant banking, global insurance and digital asset solutions.

Founded in 1959, Deltec draws upon the collective experience of more than 150 professionals. These specialists come from a wide array of backgrounds, including private bankers and investment advisors, trust officers, lawyers and certified public accountants, many of whom have previously worked at some of the world’s largest and most prestigious financial institutions. Deltec specializes in providing its clients with private banking and fiduciary expertise, fund administration, investment management solutions, digital asset financial services, insurance, and corporate and merchant banking capabilities.

Following the purchase of Société Generale’s private banking business in The Bahamas in 2016, Deltec has seen its group-wide assets under management, administration and custody rise to over $12 billion, as of late 2019 (http://nnw.fm/n0YQx).

Deltec Bank has received a number of accolades throughout its lengthy history, most recently being named the ‘Best Private Bank in the Caribbean 2020’ by Global Banking and Finance Review (http://nnw.fm/jx4rS), an award which it also won in 2015. The company was recognized for its outstanding performance and achievements, scoring particularly highly in the following categories:

  • Strong client relations with personal and client-focused services;
  • Highly personalized and innovative products and services; and
  • Continued commitment to providing clients with the best possible financial solutions.

Opportunity within Fintech

Remarkably for a private bank, Deltec Bank & Trust has historically been at the forefront of the digital banking and fintech revolution within the financial services industry. Deltec has also gained renown for its annual conference, with the latest iteration focusing on disruption with financial services (http://nnw.fm/3m0kX). Hosting over 300 delegates, including the Deputy Prime Minister & Minister of Finance of The Bahamas, the conference featured ‘The Innovator’s Marketplace’, a forum providing an opportunity for emerging companies in biotech/life sciences, virtual reality, blockchain, fintech, quantum computing and other cutting-edge industries to pitch their ideas to investors and attendees in 45-minute presentations.

Engagement with the Community

Deltec Bank has long held strong ties within the local community in The Bahamas through its Deltec Initiatives Foundation, which was designed to foster an environment that empowers young Bahamians to drive positive social impact through the power of arts, entrepreneurship and education.

Since 2013, the foundation has discovered, launched and mentored many talented, motivated and driven Bahamian artists, artisans and entrepreneurs. The Deltec Initiatives Foundation comprises three pillars: The Initiative for the Arts, The Initiative for Young Entrepreneurs and The Initiative for Scholarship & Education.

Expert Team of Professionals

Jean Chalopin, chairman of Deltec International Group, is a global business leader with a remarkably diverse background encompassing several industries, including banking, wealth management, biotechnologies and entertainment.

Odetta Morton, CEO of Deltec Bank & Trust, is a seasoned banker and CPA with over 20 years of experience in the financial services sector, including financial management, shareholder relations, business leadership and corporate strategy.

Gregory Pepin, Deputy CEO of Deltec Bank & Trust, is an expert financial strategist with vast experience in blockchain technology, investments, wealth management and insurance.

Fabio Gama, Chief Operating Office of Deltec Bank & Trust, has 15 years’ experience in the financial services industry, Fabio has been directly responsible for operations, IT, facilities and procurement. He is an expert in developing teams and has a proven track record for supporting business needs.

Tanya Carey, Chief Financial Officer of Deltec Bank & Trust, is a resourceful finance professional and licensed CPA with over 20 years of experience in financial services and solid industry and regulatory knowledge.

Terry Girling, Chief Administrative Officer of Deltec Bank & Trust, is a senior executive, chartered accountant and banking professional with over 40 years of experience in the finance and banking sectors. Girling is experienced in all facets of banking, including accounting, compliance, operations, technology, fund administration, trust administration and human resources.

Hugo Rogers, Chief Investment Officer of Deltec Bank & Trust, is a multi-asset investment and award-winning global equity and hedge fund manager. He has actively managed investments for over 15 years. He is also a CFA Charterholder with a master’s degree from Oxford University.


Recent News

chart

Trxade Group Inc. (NASDAQ: MEDS)

The QualityStocks Daily Newsletter would like to spotlight Trxade Group Inc. (NASDAQ: MEDS).

Trxade Group (NASDAQ: MEDS), an integrated drug procurement, delivery and healthcare platform, on Monday provided its financial results for the second quarter ended June 30, 2020. Among the highlights, Trxade reported record revenues and an increase in growth profit. “The second quarter financial results, which showcased a 244% increase in revenues to a record $6.6 million and 72% increase in gross profit to $2.0 million,” Suren Ajjarapu, chairman and CEO of Trxade Group, stated in the news release. To view the full press release, visit http://nnw.fm/i9WhO

Trxade Group Inc. (NASDAQ: MEDS) is an integrated pharmaceutical services company that offers a unique combination of a web-based purchasing platform (www.trxade.com) for transactions between independent pharmacists and drug distributors (B2B); a network of pharmacies with E-Hub software; a mail order pharmacy; and warehouse and drug delivery services. This synergistic combination of product offerings and superior data analytics is poised to benefit all stakeholders and consumers within the pharmaceutical industry.

Trxade will leverage and scale its fully integrated model to execute the following growth strategies:

  • Increase share of pharmacist drug purchasing
  • Additional SKUs and expand product breath
  • Partner with Specialty and International Mfg.
  • Expand mail order licenses to all 50 states
  • Scale Delivmeds for consumer delivery nationwide
  • Integration with telemedicine
  • M&A Opportunities within drug value chain

Founded in 2010 and headquartered in Tampa, Florida, Trxade’s overarching corporate strategy is to penetrate the existing retail independent pharmacy marketplace and diversify the company’s pharmaceutical mix with additional specialty and acute care products. Trxade is advancing on this mission by focusing on three key niches in the health care market.

Business-to-Business (B2B)

The $330 billion U.S. pharmaceutical industry is comprised of more than 65,000 pharmacy facilities and 1,500 state-licensed suppliers. Roughly 24,000 of these facilities are independent pharmacies, which collectively spend approximately $93 billion a year on branded and generic drugs.

Trxade targets these independent pharmacies, leveraging a robust, “E-Bay/Kayak-like” technology platform with optimum buyer/seller pricing algorithms, product availability, and predictive data analytics features.

Trxade currently serves and transacts with more than one-third (10,250) of these independent pharmacies and facilitates over $10 million of drug purchases a month!

Consumer

Trxade also targets the “consumer side” of the pharmaceutical industry, aiming to lower prescription drug costs by attacking the inefficient value chain; offering drug price transparency and efficient buying; and, delivering drugs DIRECT to independent pharmacists and consumers.

The company operates a full-service mail order pharmacy for U.S. consumers, as well as a mobile app called “Delivmeds” (http://www.delivmeds.com) which enables SAME DAY home delivery of dispensed prescriptions.

Retail

Trxade’s Managed Services Organization (“TrxadeMSO”) enables its member independent retail pharmacies to get patients, process orders, and deliver or ship prescriptions to patients. TrxadeMSO provides access to encompassing network of pharmacies through the E-Hub software, allowing for timely and comprehensive medication fulfillment.

These offerings ensure the best-suited pharmacy receives the patient’s information, thereby ensuring appropriate medication coverage based on the patient’s location, payor coverage, and medication access/inventory. This will save the clinicians and their staff time as they benefit from efficiency and enhanced workflow management in script processing and fulfillment.

Health Care Market

The U.S. health care market currently hovers near $4 trillion and is expected to grow as the general population ages. This growth will have greater impact on consumers as out-of-pocket expenses also rise. Additionally, drug costs are paced to increase faster than the overall health care and well above inflation.

Drug pricing is variable, and reimbursement is squeezing profits. This provides significant opportunity for the Trxade model of price visibility and profit optimization.

Trxade’s fair online market platform targets the nation’s retail community and independent pharmacies, of which there are approximately 24,000 nationwide. TRxADE has found that independent pharmacies, in order to be cost-effective, often operate with minimal staff and conduct up-to-the minute price checks. The TRxADE S2P platform gives these pharmacists the ability to easily compare the price of drugs offered by various suppliers and select the most favorable deals, saving money by taking advantage of best purchase pricing.

TRxADE’s programs include:

  • TRxADE Exchange, which opens and widens the distribution channel to the retail, community pharmacy. A purchasing pharmacy can view products from manufacturers, buying groups, and wholesalers on a real-time and continuous basis. This approach significantly enhances the competitive spirit of the exchange where the lowest price exists for each product at any given point in time. TRxADE has become a competitive tool for all progressive entities and is recognized for its easy searching of hard-to-find generic pharmaceuticals at substantially reduced prices.  
  • RX Guru™ is an industry-leading price prediction model that integrates product shortage insight into pharmacy acquisition benchmarks (“PAC”) to ascertain trends and pricing variances that result in significant purchasing opportunities. RX Guru affords members the opportunity to continuously benefit from real price purchasing opportunities that are concealed from the rest of the industry. 
  • Product Shortage Database – TRxADE maintains the most comprehensive retail, specialty and acute care pharmaceutical product shortage database in the country. Other industry competitors mainly restrict their efforts to specialty and acute care product shortages and narrowly research oral generic products. TRxADE’s advanced prediction tools help members source those hard-to-find products at affordable costs in a timely and easy-to-search process. 

Management Team 

Trxade’s management team is rich in expertise within the pharmaceutical supply chain and is supported by a base of advisors and contractors who are experts in related fields of the pharmaceutical sector.

Suren Ajjarapu – Chairman of the Board, Chief Executive Officer and Secretary
Suren Ajjarapu has served as Trxade’s chairman of the board, CEO and secretary since 2014, and as the chairman of the board, chief executive officer and secretary of Trxade Nevada since its inception. Ajjarapu also serves as a chairman of the board for Feeder Creek Group Inc., since March 2018. Ajjarapu formerly was a founder, CEO and chairman of Sansur Renewable Energy Inc., a company involved in developing wind power sites in the Midwest, United States; a founder, president and director of Aemetis Inc., a biofuels company (AMTX.OB); a founder, chairman and CEO of International Biofuels, a subsidiary of Aemetis Inc.; and a co-founder, COO, and director at Global Information Technology Inc., an IT outsourcing and systems design company. Ajjarapu holds an M.S. in environmental engineering from South Dakota State University, Brookings, South Dakota, and an MBA from the University of South Florida, specializing in international finance and management. Ajjarapu is also a graduate of the Venture Capital and Private Equity program at Harvard University.

Prashant Patel – Director, President and Chief Operating Officer
Prashant Patel has served as Trxade’s full-time president and COO, and as a director since the company’s acquisition of Trxade Nevada in 2014, and as the COO and president and as a director of Trxade Nevada since its inception. He has been a president and member of the board of Trxade since August 2010. Patel is a registered pharmacist and pharmaceutical consultant with over 10 years of experience in retail pharmacy and pharmaceutical logistics. He is the founder of several pharmacies in the Tampa Bay area, in Florida. Since 2008, Patel has been managing member of the APAA LLC pharmacy. Since 2007, Patel has been a vice president of Holiday Pharmacy Inc. Patel graduated from Nottingham University School of Pharmacy and practiced in the United Kingdom before obtaining his masters in Transport, Trade and Finance from Cass Business School, City University, UK.

Trxade Group Inc. (MEDS), closed Tuesday's trading session at $7.96, up 26.7516%, on 902,699 volume with 6,834 trades. The average volume for the last 3 months is 44,287 and the stock's 52-week low/high is $3.29999995/$11.6000003.

Recent News

chart

PowerBand Solutions Inc. (TSXV: PBX) (OTCQB: PWWBF) (Frankfurt: 1ZVA)

The QualityStocks Daily Newsletter would like to spotlight PowerBand Solutions Inc. (TSXV: PBX) (OTCQB: PWWBF) (Frankfurt: 1ZVA).

PowerBand Solutions (TSX.V: PBX) (OTCQB: PWWBF) (Frankfurt: 1ZVA), today announced that Royal Administration Services, Inc. ("Royal Admin"), a provider of automotive insurance products across the United States, will be recommending dealers use the PowerBand virtual transaction platform for drivers and dealers. Royal Admin entered the agreement with PowerBand's strategic partner and investor, Texas-based D&P Holdings, Inc. ("D&P"), under which it will direct dealerships to the PowerBand platform. To view the full press release, visit http://nnw.fm/mj8Et

A Better Way to Connect and Acquire Vehicles

PowerBand’s mission is to create an online, consumer-directed marketplace that streamlines the interactions among all participants in the automotive industry. It transforms today’s antiquated business model with speed, transparency, access to information and ease of use for consumers and dealers.

Consumers can easily connect with new sources to buy vehicles, network with motivated buyers and sellers, maximize their trade-in values, improve their customer experience. PowerBand’s standardized system and transaction process also increase efficiencies and benefits with hands-on, process-driven, in-store training and support.

Through internal development, acquisitions, joint ventures and strategic partnerships, PowerBand is developing solutions for consumers, dealers, manufacturers, commercial customers and lenders that are poised to transform the trillion-dollar U.S. automotive industry.

The PowerBand Auto Platform

PowerBand’s transaction platform was developed by a team of experienced automotive, technology and finance experts, and has been refined through years of operational experience. Built on the core belief that the consumer prefers to primarily conduct automotive transactions online and avoid interactions with unnecessary middlemen, PowerBand’s product solutions include:

  • Leasing: PowerBand is currently licensed in 33 U.S. states via a majority interest in MUSA Auto Finance LLC, an advanced online leasing technology platform that has transformed the new and used vehicle leasing industry. A partnership with Tesla was recently finalized, making MUSA the only approved, non-captive lease partner for Tesla in the U.S.
  • Inventory and Financing: A partnership with RouteOne LLC, a leading financial platform founded in 2002 by Ally Financial, Ford Motor Credit Co., TD Auto Finance and Toyota Financial Services, allows access to a network of more than 18,000 dealerships and 1,400 financing sources.
  • Auction Platform: PowerBand and its joint-venture partner, D2D Auto Auctions, are developing a direct consumer-to-dealer and a consumer-to-consumer automotive portal, which will provide an innovative alternative to physical dealership and auction locations.
  • LiveNet Auction: An online platform portal that allows dealers to create instant live vehicle auctions to a vast network of the industry’s top used vehicle buyers.
  • MarketPlace Auction: An online listing auction site for buying and selling automotive inventory – ideal for dealers, fleet, OEM and rental companies.
  • Used Vehicle Inspections: An LOI agreement with TÜV NORD Mobility Inc., a German-based global leader in vehicle inspections operating in more than 70 countries, will provide the most comprehensive, certified vehicle inspection reports available in North America. Appointments booked within the platform can be performed nearly anywhere.
  • Product Development: PowerBand’s comprehensive consumer solution, Driveaway, will be a fully transactional consumer marketplace where dealers and consumers can buy, sell, trade-in and finance vehicles, often in seconds, from the comfort of their home.

Automotive’s Growing Markets

The automotive dealership and commercial fleet vehicle auction industry is a $100-billion sector with more than 40 million used vehicles transacted in the U.S. each year. Of those, ten million are sold through auctions. From 2013 to 2017, the growth of online-only auctions far outpaced physical auctions, growing at a 33% compound annual growth rate compared to 2% CAGR at physical auctions.

Automotive leasing is another large, growing and fragmented market, generating approximately $120-billion in annual revenue. As a percentage of vehicle sales, leasing reached 30% in 2018, up from 21% in 2012, and is seen as a substantial opportunity for PowerBand and MUSA Auto Finance. Using proprietary technology and by focusing on high-quality, credit-worthy customers, MUSA grew its automotive lease originations to $182 million.

Disrupting Auto Leasing with MUSA

Legacy solutions are complicated, expensive and slow at processing leases. MUSA’s first-of-its-kind technology platform eliminates third-party decisions and the human capital required in the underwriting process. MUSA’s platform navigates the entire customer experience – underwriting, funding and the delivery process – within minutes. Leases can be approved in seconds.

PowerBand’s acquisition of MUSA brings together two leading-edge companies with the vision to become a one-stop platform for the entire vehicle purchase lifecycle.

Experienced Leadership

PowerBand is led by a collection of automotive veterans with a passion to collectively and positively impact the industry.

  • Kelly Jennings, president and CEO, is the founder of PowerBand Solutions and a franchise dealer owner/operator with more than 27 years of automotive experience. Jennings received General Motor’s Triple Crown Award, Ford Motor Company President’s Award and Honda Canada’s Excellence Award.
  • Darrin Swenson, COO of PowerBand and D2D Auto Auctions/Hunt Automotive Group, has more than 25 years of automotive/auction experience.
  • Jeff Morgan, CEO MUSA, holds over 25 years of experience in the auto finance sector.

 

PowerBand Solutions Inc. (OTCQB: PWWBF), closed Tuesday's trading session at $0.1733, up 0.17341%, on 4,000 volume with 1 trade. The average volume for the last 3 months is 95,328 and the stock's 52-week low/high is $0.038600001/$0.241600006.

Recent News

chart

Kingman Minerals Ltd. (TSXV: KGS)

The QualityStocks Daily Newsletter would like to spotlight Kingman Minerals Ltd. (TSXV: KGS).

Kingman Minerals (TSX.V: KGS), a Canada-based company engaged in the acquisition, exploration and development of gold and silver properties in North America, uses modern technology to extract remaining wealth left behind by previous generations. KGS is favorably positioned to benefit from the current bullish nature of the gold sector, which has seen its strongest gains since 2010 with the upward trajectory expected to continue. To view the full article, visit: http://nnw.fm/yrjX6

Kingman Minerals Ltd. (TSXV: KGS), formerly Astorius Resources Ltd., is engaged in the acquisition, exploration and development of gold and silver properties in North America. The Canada-based company is focused on sourcing and developing high-quality properties in favorable mining locations to advance its diverse portfolio of low-cost, lifelong assets.

Kingman Mine

The Company maintains the following projects:

The Mohave Project: Located in the Music Mountains in Mohave County, Arizona. Approximately 35 miles from the town of Kingman, the property consists of 20 lode claims, including the historic Rosebud Mine. The Company has entered into an option agreement to earn 100% over four years. According to historic mappings of the mine, probable ore is 15,560 tons. Possible (inferred) ore is comprised of 176,000 tons, and additional possible (inferred) ore totals slightly over 1,100,000 tons. The total contained gold ounces for all categories is estimated at 664,000 ounces, and contained silver is estimated at 2,600,000 ounces. The Company has recently completed two underground reconnaissance and sampling programs and is in the process of verifying previous resource estimates.

 

The Cadillac East Property: Located approximately 55 kilometers east of Val d’Or, a hub for exploration and mining activities in the Canadian province of Quebec. The Company acquired a 100% interest in the property from an arm’s length vendor. Cadillac East Property consists of 12 claims, and the Company has an option agreement to earn 100% over three years. Having been the subject of numerous geophysical and geological surveys, the Cadillac East Property has been explored and surveyed by numerous companies as well as by the Quebec government. Exploration work done in 2017 by Exploration Facilitation Unlimited Inc. revealed multiple potential targets for future investigation, as results from the soil program identified value in gold, silver, copper, zinc and nickel.

Kingman Minerals is focused on enhancing shareholder value as it continues exploring potential assets and acquiring strategic gold targets. The company recently commissioned mining consulting services company Burgex Mining Consultants Inc. to complete two underground gold exploration programs in the historic Rosebud Mine. Burgex specializes in mineral exploration, mining claim staking, landman services, mining consulting, and the access and documentation of abandoned mine sites throughout the western United States and the world. Burgex’s founders have been active in the industry since 2007 and have identified, secured and consulted on hundreds of thousands of acres of mineral properties spanning a wide range of mineral commodities with billions of dollars’ worth of resources and reserves. The Burgex team has been featured in Forbes Magazine as well as on the Discovery Channel and other outlets. Burgex is at the vanguard of industry advancements in safely accessing difficult vertical abandoned mine workings and continues to pioneer new mineral exploration methods with strategic partners throughout the United States and the world.

Gold’s Predicted Rise

The value of gold is currently on an upward climb due to COVID-19’s upending of the global economy, causing governments to expand their balance sheets. In 2019, as a result of the housing and financial crisis, gold saw its best performance since 2010increasing as much as 20% and hitting a top price of $1,549 per ounce in September of that year. Analysts predict its price will continue to climb due to strong buying by central banks, a weakening of the U.S. dollar, and increasing political tensions. A recent Wolfe Research report predicted gold would hit an all-time high, referencing an ounce of gold that commanded a $1,515 asking price. As the value of the U.S. dollar weakens, the demand for gold is inversely rising. Known as a safe-haven asset, gold tends to see increased levels of demand during times of consumer fear or recession.

Management

Sandy MacDougall – Chairman and Director
An economics graduate from the University of British Columbia, Sandy MacDougall brings 30+ years of experience in the investment banking and finance industry to KGS. He was instrumental in the acquisition, development and production of gold at the Alto el Toro mine near Ibaguel, Columbia. As a former investment advisor at Canaccord Capital Corp., MacDougall was a key player in multiple significant financings in Canada as well as abroad, working with a wide range of companies. His experience has afforded him critical exposure to precious and base metal projects throughout North and South America, and he has served as chairman of the board since 2016.

Arthur Brown – President and Director
With 36 years of business experience and service to the boards of eight other companies in sectors ranging from technology to oil, gas and mineral exploration, Arthur Brown adds substantial knowledge in corporate structure and development as well as financings and venture capital to the KGS team.

Cyrus Driver – Independent Director
Cyrus Driver was a founding partner in the firm of Driver Anderson from its inception in 1982 and is a chartered accountant as well as a retired partner in the firm of Davidson and Company LLP. Aside from providing general public accounting services to a diverse range of clients, his specialty is servicing TSX Venture-listed companies and members of the brokerage community. With expert knowledge of the securities industry and its regulations, Driver lends valuable advice to his clients regarding finance, taxation and other accounting-related matters. He currently serves as director and chief financial officer of several TSX-V-listed companies.

Dr. Peter Born – Director and Technical Specialist
A professional geologist registered with the Association of Professional Geoscientists of Ontario and a fellow of the Geological Association of Canada, Dr. Peter Born brings 30+ years of experience in exploration and mining to the company. With prior roles as a senior geologist with Western Mining Corporation, he is currently working with RPS Energy Canada Ltd. on natural gas plays related to high-temperature dolomites and sedimentary zinc deposits (MVT) within the Appalachian Basin in the United States. Dr. Born holds a Ph.D. in earth sciences and has expertise in Precambrian sedimentary geology, basin analysis, sedimentology, stratigraphy and sedimentary ore deposits.

Kingman Minerals Ltd. (TSXV: KGS), closed Tuesday's trading session at $0.09, up 5.88%, on 24,000 volume with 3 trades. The average volume for the last 3 months is 105,160 and the stock's 52-week low/high is $0.07/$0.22.

Recent News

chart

Sugarmade, Inc. (SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (SGMD).

Sugarmade, Inc. (OTCQB: SGMD) Last year, Judiciary Committee Chairman Jerrold Nadler teamed up with Senator Kamala Harris to file legislation that would end federal prohibition of cannabis in the country and seek to repair some of the damage done by the decades’ long war on drugs. The Marijuana Opportunity Reinvestment and Expungement (“MORE”) Act would remove marijuana and THC from the Controlled Substances Act, provide for the expungement and resentencing of prior marijuana convictions and prevent federal agencies from using cannabis as a reason to deny access to benefits or citizenship status for immigrants.

Sugarmade, Inc. (SGMD) is headquartered in Monrovia, California, where the company recognizes new opportunities in the cannabis delivery space and in the market for supplies to the quick-service restaurant industry – both of which have fast-changing dynamics due to the recent outbreak of coronavirus in the United States.

The Coronavirus Cannabis Boom Market

Retailers across the nation are closing their doors and curtailing operations due to the coronavirus pandemic, inherently pinching sales. In the California cannabis sector, however, business has never been better – especially relative to home delivery.

California’s cannabis industry continues to operate, and media reports reveal booming cannabis sales as the state’s citizens stay home to wait out current events. The Los Angeles Times recently published the headline, “Marijuana Sales on Fire amid Virus Outbreak; New York Post “Cannabis sales hit new highs”; USA Today “American Stock Up on Pot” Fox News “California marijuana sales surge”; and ABC News Cannabis Shops thrive in coronavirus pandemic.

The state of California benefits from the ultra-high taxes paid by the highly regulated cannabis industry, and has thus deemed cannabis companies as “essential” businesses, allowing for full operations to continue. While pot shops are seeing strong foot traffic, the real growth action is in-home delivery as consumers seek to embrace social distancing. Many delivery operators are reporting difficulty in meeting demand with sales growth of up to 10% sequentially each week. It is certainly a boom time for the industry.

Sugarmade Growth Strategy

Recognizing new investment and operational opportunities within California’s cannabis market, Sugarmade is strategizing to take advantage of opportunity specifically in delivery services (non-storefront retailer), manufacturing via co-branding, and selective genetic cultivation. The company is taking a highly selective approach, targeting only the best of these opportunities for company growth.

In line with this strategy is northern California delivery service Budcars, in which Sugarmade owns a 40% interest and an option to gain a controlling interest. Budcars connects consumers with premium products sourced from top-tier farms and extractors, offering a curated menu of fully compliant cannabis products. The company maintains a competitive advantage by sourcing premium cannabis offerings and same-day delivery. In addition to maintaining its own cars, California licenses, and fulfillment center, Budcar orders its premium products in bulk at lower prices, enabling the company to rein in costs and maintain competitive pricing for its customers. Currently serving major communities within the metropolitan area of Sacramento, Budcars plans to continue the expansion of the company’s delivery reach.

Sugarmade plans to continue its expansion into burgeoning new sectors of the cannabis market through the following avenues:

  • Geographic expansion of Budcars delivery scope
  • New delivery geographies
  • Cannabis cultivation as a key component of a hybrid vertical integration strategy
  • Product technology expansion—including products containing exotic and lesser-known cannabinoids

 

Diversified Portfolio

Sugarmade has positive market exposure to cannabis delivery, as well as to the restaurant industry, at a time when these businesses are being force to move toward take-out and delivery models in order to survive.

The company has various business operations in diverse marketplaces, including food, safe packaging and sanitary supplies for various industries, and agricultural supplies. Sugarmade entered the industrial hemp and CBD space by investing in Hempistry, Inc., a privately held Nevada corporation. Hempistry began planting an ultra-high cannabidiol (CBD) industrial hemp strain on a land option it holds on 5,000 acres of prime Kentucky farmland. The strain of industrial hemp being grown by Hempistry is ultra-rich in CBD but contains less than 0.3% of THC, the psychoactive ingredient found in cannabis.

CarryOutSupplies.com, the leader in paper and plastic take-out supplies, serves nationwide customers by offering a wide array of high-quality products that are cost-efficient, custom-made and delivered on time. This business unit currently serves 2,000 quick service restaurants, garnering from 30%-40% of the market share. Sugarmade plans to expand operations via the addition of market share and the introduction of new product offerings.

Market Opportunity

There is little doubt among industry participants, and recently confirmed by Forbes, that California is the single largest cannabis market in the world. The state is expected to produce more than $3.5 billion in cannabis sales during 2020, with growth topping 23% annually. The global industrial hemp market size was estimated at $4.71 billion in 2019 and is expected to register a revenue-based CAGR of 15.8% over the forecast period of 2016-2027, according to Grandview Research. Market growth drivers include the 2018 Farm Bill and society’s increasing knowledge of the benefits of hemp products.

Overall industry growth is great, but specific vertical sector growth is even better. Cannabis delivery is clearly the fastest growing sector of the marketplace and with coronavirus fears the already robust growth rate has accelerated.

Sugarmade seems to be in the right industry at the right time in history.

Management

CEO Jimmy Chan is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, and international manufacturing and importation. He is also the founder of CarryOutSupplies.com, a company that revolutionized the custom-printed paper supplies subsector of the quick-service restaurant industry, which merged with Sugarmade in 2014.

Dedicated to getting the highest caliber of THC and CBD to its customers’ door, the company’s priority is to ensure that they receive the highest quality cannabis product free from logistical hassles. Sugarmade specializes in growing and acquiring innovative brands to maximize value for company employees, shareholders and other stakeholders. Sugarmade believes its future is very bright as the company expands operations within the cultivation sector and rapidly increases its revenue base.

Sugarmade, Inc. (SGMD), closed Tuesday's trading session at $0.00215, up 2.381%, on 44,275,214 volume with 272 trades. The average volume for the last 3 months is 65,398,727 and the stock's 52-week low/high is $0.001599999/$0.021999999.

Recent News

chart

InsuraGuest Technologies, Inc. (TSX.V: ISGI)

The QualityStocks Daily Newsletter would like to spotlight InsuraGuest Technologies, Inc. (TSX.V: ISGI).

InsuraGuest Technologies (TSX.V: ISGI), through its wholly owned U.S. Hospitality subsidiary InsuraGuest, today announced that it has gone live with end-to-end vacation rental property management software provider Hostfully. According to the update, the InsuraGuest(R) Hospitality Liability coverages can now be purchased by the Hostfully client. To view the full press release, visit http://nnw.fm/d0SNq

InsuraGuest Technologies, Inc. (TSX.V: ISGI) is a leading global SaaS (Software-as-a-Service) company leveraging its proprietary, flagship insurtech (insurance + technology) software, InsuraGuest, which is integrated with the property management systems of hotels and vacation rentals to deliver custom Hospitality Liability coverages.

InsuraGuest’s Hospitality Liability coverages are purchased by hotels and vacation rental properties, which can address claims from guests and their room occupants. The combination of the integrated software and customized insurance provides the property liability coverages the guests benefit from in the event a loss is incurred during their stay.

The Hospitality Liability policy is offered through integration of InsuraGuest’s API with the clients’ property management systems. InsuraGuest’s platform is currently capable of integrating with approximately 71 different hotel and vacation rental property management systems, giving it access to millions of rooms worldwide.

InsuraGuest continues to pursue expansion opportunities in the United States, and has plans to expand to its distribution platform and Hospitality Liability coverages to the United Kingdom and Europe regions by third quarter 2020, as well as expansion into Asia by the end of 2020.

Protection that Enhances the Guest’s Experience

InsuraGuest’s Hospitality Liability coverages add a layer of protection for the property on a primary basis, should a guest experience an accident or theft while staying at an InsuraGuest member hotel or vacation rental property.

Market Opportunity

The U.S. hotel industry generated more than $218 billion in annual revenues in 2018, an increase of $10 billion from the previous year, according to STR’s 2019 HOST Almanac. The European market is more than double the size of the U.S. market. According to Oxford Economics, there were 6.4 billion nights stayed in the world, with 2.6 billion hotel nights stayed in Asia, 2.8 billion nights stayed in Europe, and 1.1 billion stayed nights in the United States. Additionally, $100 billion was spent on vacation rentals in the United States, where there approximately 4.5 million second homes are being managed by a third-party rental company.

With distribution in Europe and the United States, InsuraGuest’s combined demographics will total 3.9 billion nights stayed, and will more than double its vacation rental opportunities.

Within this burgeoning, high-demand industry is risk of liability to guest injury. For example, gym injuries are among the top five most common hotel accidents. Without proper hedges in place, the property may be liable in a personal injury claim or lawsuit that are not the properties fault.

Though the potential for accidents, slip and falls and mishaps can be widespread, it can be covered under the InsuraGuest Hospitality Liability policy to provide guests a worry-free and enjoyable stay that potentially increases loyalty for the property.

Investment Consideration

  • Targeting hotels and vacation rentals, a multi-billion-dollar industry
  • Providing the first line of defense in case of accident, loss or death
  • Expanding distribution reach with footing in European hotel and vacation rental markets
  • Expansion into Asia by 2020

Executive Team

Douglas Anderson, Chairman & Chief Executive Officer
Douglas Anderson has been a businessman in the real estate industry for nearly 30 years. His business expertise includes master planning and development implementation for larger-scale resorts, business parks and commercial developments across the USA and two provinces in Canada. His business endeavors include the founding of the 7th larger private equity fund in America focusing on multifamily and senior care (ROC Fund/Bridge IPG Fund). He serves as chairman/founder of a golf and winter sports ski holding company with operations in four major east coast markets and British Columbia, Canada.

Anderson earned a Bachelor of Science in consumer studies with an emphasis in architecture as an undergraduate at the University of Utah. He subsequently earned his MBA. He also attended a three-year OPM Program a postgraduate business education at Harvard Business School in Boston. Anderson is an avid skier and outdoor enthusiast.

Logan Anderson, CFO & Director
Logan Anderson (bachelor’s degree in communications, accounting and economics) holds the designation of ACA with the Chartered Accountants of Australia and New Zealand. He began his career as an associate chartered accountant in New Zealand and then Canada. This was followed by his position as controller of a management services company which was responsible for the management of numerous private and publicly traded companies. Since 1993, Anderson has served as president of Amteck Financial Corp. (and its predecessors), a private financial consulting services company servicing both private and public companies. He is a former director of 3D Systems, Inc. (NYSE: DDD), and was formerly a founder, officer, and director of Worldbid.com. Anderson has also been involved in raising funds for numerous private and public companies in all stages of their development and has been an officer and director for numerous public and private companies over the past 40 years.

Charles James Cayias, President & Director
Charles James Cayias is also the president and owner of Charles James Cayias Insurance Inc. He is a third-generation insurance professional whose creativity and artistic vision have enabled him to establish a full-service agency combined with the personal service each client deserves. His outstanding people skills, honesty, integrity and fairness are evident by his loyal and growing clientele, the majority of which are referrals who become long-time customers and friends. Cayias began his insurance career in the early 1970s and has been licensed since 1977. He is licensed in all 50 states and specializes in niche programs. He has extensive expertise in all aspects of the insurance industry including commercial insurance, employee benefits, workers’ compensation, professional liability, risk management and bonding.

Tony Sansone, COO & VP of Finance
Tony Sansone has over 30 years of financial, operations and business development experience which includes serving as CFO in the health care, foodservice distribution, manufacturing and technology sectors, including public company experience. He has held senior finance positions in the banking, telecommunications, medical products, and food & drug retailer industries, closing over $430 million of private debt, equity and line of credit financings and over $350 million of a merger, acquisitions, real estate and state incentive transactions, including due diligence, negotiations, closing, and integration. Sansone coordinated and was the executive sponsor for four ERP implementations and multiple other best-in-class software & technology solutions. He received his MBA from the University of Utah and a Bachelor of Science in accounting from Utah State University. Sansone also currently serves as president-elect of the Utah Chapter of Financial Executives International and a past president and current member of the board of trustees for Catholic Community Services of Utah. He is the proud father of three children.

Christopher J. Panos, Vice President & Director
Christopher J. Panos is a highly competitive sales professional with over 15 years of territory manager sales experience and an award-winning record of achievements. He is exceptionally well organized with a proven work history that demonstrates self-discipline, superb communication skills, and the initiative to achieve both personal and corporate goals. Panos is successful in building relationships with a large network of industry professionals in order to grow and maintain new and existing business, exceed new sales objectives and provide in-depth product training to authorized dealers and sales personnel.

Alexander Walker III ESQ, Corporate Counsel & Director
Alexander Walker III ESQ has served as director of the company since September of 2018 and as counsel to the company since July of 2018. Walker is an attorney and has been a member of the Utah Bar Association since 1987 and a member of the Nevada State Bar since 2003. His practice has involved general business litigation, in both federal and state courts, and transactional work, including securities offerings and registration, corporate formation and periodic reporting compliance. Walker has provided legal services to emerging businesses throughout his carrier and at times has served as an officer and board member as well as legal counsel public companies. His duties as legal counsel for a public company engaged in the business of ownership and operation of coal-producing properties in the western United States included oversight of corporate-related legal matters including securities reporting, corporate compliance, federal and state mining regulation, and employment law oversight. He also has served as the chair of the Mining Committee of the Energy, Natural Resources and Environmental Law Section of the Utah State Bar, a member of the board of directors of the South East Utah Energy Producers Association, the co-chair of the board of the Western Energy Training Center, a board member of the Utah Supreme Court Committee to Review the ABA Recommendations Regarding the Office of Professional Conduct, and a board member of the University of Utah Crimson Club.

Jennifer Epperson, Vice President of Sales
Jennifer Epperson has over 20 years of B2B sales experience with exceptional success history. She has grown and developed sales territories across multiple industries. Her ability to find and develop strategic relationships has given her top-level performance throughout her career. Epperson’s passion and knowledge provide an inherent ability to connect and retain relationships for the growth of the company. Throughout her professional career, she has achieved peak performance sales results and awards year after year. She captures the vision of the company and drives it forward with enthusiasm and expertise. Her commitment to providing an exceptional customer experience has been the key to her success.

Richard Matthews, Interim Financial Controller
Richard Matthews joined the InsuraGuest team in March 2019 as the interim financial controller. Leading the Finance and Audit team, Matthews is responsible for the delivery of financial services such as accounting, treasury, reporting, budgeting and insurance management, in accordance with legislative requirements and organizational policies and strategies. He has over 30 years of experience in providing professional services across a broad range of finance areas including compliance, business process, audit, and financial reporting. He holds a degree in accounting from the University of Utah and is a licensed CPA in the state of Utah.

Roger Bloss, Corporate Consultant & Board Advisor
Roger Bloss joined InsuraGuest in August of 2019 to advise the company and its board on hotel transactions, contributing his knowledge from more than 40 years in the hospitality industry. Bloss previously served in executive positions with several major hotel franchise companies and in 1996 founded Vantage Hospitality Group hotel brands. Under his leadership, Vantage became a Top 10 global hotel company and made the Inc. 500/5000 list of Americas’ fastest-growing private companies for eight straight years. Bloss was named Lodging Magazine’s “Innovator of the Year” in 2006 and 2010, and in 2009 earned a spot on HSMAI’s “Top 25 Extraordinary Minds in Sales and Marketing.” Bloss joined Red Lion Hotels Corporation (RLHC) in September 2016 in conjunction with the acquisition of Vantage.

Jim Kilduff, Board Advisor
James “Jim” C. Kilduff has nearly 40 years of experience in the insurance and risk management sectors. He is a dynamic and energetic team leader and builder with extensive experience in the changes affecting the insurance business through Gas, alternative distribution, insurtechs and program business. His skillset includes experience as chief insurance officer with Outdoorsy Insurance Group, CEO with Harbor Hill Solutions Inc., and senior vice president and chief marketing officer with State National Insurance Companies. His career has spanned MGA creation and management, insurance company management, business development and underwriting, primary insurance and reinsurance.

Don Archibald, Board Advisor
Don Archibald brings to InsuraGuest’s advisory board 54 years of experience as an insurance agent. Archibald is the founder and former owner of Archibald Clarke and Defieux (ACD Insurance), as well as the co-founder and former equity partner of Sussex Insurance, and an agent with Sussex since 2014.

InsuraGuest Technologies, Inc. (TSX.V: ISGI), closed Thursday's trading session at $0.17, even forthe day, on 4,500 volume. The average volume for the last 3 months is 6,228 and the stock's 52-week low/high is $0.045/$0.34.

Recent News

chart

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

Predictive Oncology (NASDAQ: POAI) was featured today in a publication from BioMedWire, examining how the naked mole-rat (“NMR”) has the same size as the normal mouse and is also a burrowing rodent. The hairless rodent has been attracting a lot of attention from scientists due to its capability to resist cancer, its impressive ability to survive without oxygen for 18 minutes, and its unusually long lifespan. One of the researchers has decided to research to determine the mechanisms behind the naked rat’s remarkable resistance to cancer.

Predictive Oncology (POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.

Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:

  • A database of clinically validated historical and outcome data from patient tumors
  • An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
  • A “smart” patient-derived tumor profiling platform
  • An in-house bioinformatics artificial intelligence (AI) platform
  • A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
  • An FDA-approved fluid collection and disposal system

Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from the company’s trove of more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies. This database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory without the use of rats or mice, allowing for the identification of biomarkers indicative of cancer. This methodology “fools” the tumor into thinking it is still in the body. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and helps categorize an individual patient’s heterogeneous tumor samples to enable development of patient-specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY® System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Competitive Advantage

Precision medicine has become the holy grail of cancer therapeutics. Data driven predictive models of tumors and their responses are critical in both new drug development and individualized patient treatment. The race has begun to model various tumors, which takes 5 to 7 years of clinical evaluation to establish historical and outcome data.

Predictive Oncology enjoys significant competitive advantage. The company already has a vast historical collection of tumors and related data, plus the ability to obtain existing associated outcome data. While others wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine to reality. Predictive Oncology already has the clinical data, including how a tumor responded to certain drugs, an in-house bioinformatics AI platform, and only needs to do the tumor sequencing. The significance is underscored by the collaboration with UPMC Magee-Women’s Hospital, designed to reveal which mutations responded to which drug then develop powerful predictive models for future testing and treatment.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Gerald Vardzel, President of Helomics, has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.

Dr. Mark Collins, Chief Information Officer of Helomics, has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.

Predictive Oncology (POAI), closed Tuesday's trading session at $1.64, off by 6.2857%, on 944,385 volume with 2,102 trades. The average volume for the last 3 months is 1,193,504 and the stock's 52-week low/high is $1.25/$6.94000005.

Recent News

chart

Sustainable Green Team Ltd. (SGTM)

The QualityStocks Daily Newsletter would like to spotlight Sustainable Green Team Ltd. (SGTM).

Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, today announced completion on a dual line mulch bagger and fully automated electric grinding screening operation. According to the update, construction was completed in Waste Management’s (“WM”) landfill facility located in Apopka, Florida, through its strategic alliance announced in October 2019. To view the full press release, visit http://nnw.fm/C0qYo

Sustainable Green Team Ltd. (OTC: SGTM), through its subsidiaries, including National Storm Recovery LLC (DBA Central Florida Arbor Care and Mulch Manufacturing Inc.), provides tree services, debris hauling, removal and bio-mass recycling, manufacturing, packaging and sales of next-generation mulch products. The company’s primary corporate objective is to provide a solution for the treatment and handling of tree debris that is historically sent to local landfills and disposal sites, creating an environmental burden and pressure on disposal sites around the nation.

Environmentally Friendly

SGTM and the solutions provided by its Sustainable Green Team are founded in sustainability. The company’s vertically integrated operations begin with the collection of tree debris through its tree services division and collection sites. Tree bio-mass is then moved through the processing division for recycling and manufacturing into a variety of organic, attractive, next-generation mulch products to be packaged and sold to retailers, landscapers, installers and garden centers.

The company’s solutions create a synergistic and environmentally beneficial solution to tree and storm waste disposal that historically has created an environmental burden on landfills and disposal sites around the nation.

SGTM’s customers include governmental, residential and commercial customers and now big box retailers. The company is headquartered in Florida.

Strategic Acquisition

SGTM in February 2020 acquired 35-year-old industry leader and innovator Mulch Manufacturing Inc., an Ohio corporation. Structured as a share exchange, this strategic partnership provides SGTM with a significantly larger footprint in the mulch industry.

The acquisition includes Mulch Manufacturing’s national and international distribution agreements, an increase in production and packaging capacity, and its sales contracts with numerous big box retailers. Mulch Manufacturing includes mulch production, sawmill operation, Natures Reflections colorant manufacturing and equipment manufacturing.

Next-Gen Products

SGTM’s vision and commitment to the environment is paired with Mulch Manufacturing’s revolutionary “next-generation” mulch product, Nature’s Reflection’s Softscape®.

Softscape mulch products, created from natural forest products, are color-enhanced with environmentally safe colorants to provide four-year color retention and are free from contaminants. Safe for people and pets, Softscape allows water and air to penetrate soil and roots, which is vital to plant health and growth.

Expansion Plans

SGTM plans to expand its operations through a combination of organic growth, through its partnership with a nationally recognized waste disposal company, and through strategic acquisitions that are both accretive to earnings and positioned for rapid growth from the resulting synergistic opportunities identified.

The company has received final zoning approval for its 100-acre site, located in Lake County, Astatula, Florida, which will serve as its flagship tree debris collection site. The facility will also house the company’s mulch manufacturing, soil composting and production bagging. This prime location includes a 5,000-square-foot building that contains warehouse and office space. The 100-acre property can accommodate millions of cubic yards of organic debris and will allow SGTM’s debris hauling division to realize significant savings on its transportation costs.

SGTM has chosen as its new headquarters the 100,000-square-foot Mulch Manufacturing building in Jacksonville, Florida. The facility comprises centralized operations of Mulch Manufacturing Inc. and National Storm Recovery LLC and has ample room to expand as needed.

Leadership

SGTM’s leadership team boasts more than 40 years of next-level experience with mulch manufacturing, treating and caring for trees. This team is guided by a roster of highly qualified professionals:

  • Tony Raynor, Chief Executive Officer
  • Edward Lee, Chief Operating Officer
  • Ralph Spencer, Director of Business Development, Strategic Acquisitions
  • Steve Ogden, ISA-Certified Arborist
  • Rick Starcher, Master Chemist
  • Peder K. Davisson, Esq., Corporate/Securities Counsel

Sustainable Green Team Ltd. (OTC: SGTM), closed Tuesday's trading session at $1.10, off by 8.3333%, on 990 volume with 8 trades. The stock's 52-week low/high is $0.05/$2.19000005.

Recent News

chart

Sharing Services Global Corporation (SHRG)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRG).

In an economy becoming more and more reliant on gig workers, or independent contractors, Sharing Services Global Corporation (OTCQB: SHRG) has designed an opportunity that offers what a “Harvard Business Review” study notes are the four top connections these independent workers are looking for (http://nnw.fm/c3Vcv).

Sharing Services Global Corporation (SHRG), formerly Sharing Services Inc., is a diversified company dedicated to maximizing shareholder value, operating through two primary subsidiaries: Elepreneurs Holdings, a direct-selling company, and Elevacity Holdings, a products company. Headquartered in Plano, Texas, SHRG markets and distributes Elevate-branded health and wellness products through an independent sales force of distributors called Elepreneurs.

Proprietary Products

SHRG’s current exclusive Elevate product offerings are marketed under the Elevacity brand, so named to signify the company’s commitment to elevating lives.

The Elevate health and wellness product line consists of nutraceutical products that SHRG refers to as D.O.S.E., which stands for dopamine, oxytocin, serotonin and endorphins – all of which are key hormones proven to promote happiness and well-being.

Elevacity brand products are carefully formulated, chosen and designed to support a single objective: elevate the happiness and well-being of the consumer.

Global Network of Elepreneurs

Elevacity products are shared and sold by a growing international network of home-based entrepreneurs, called Elepreneurs, operated by Elepreneurs Holdings. This SHRG subsidiary provides basic and advanced programs for both new and experienced entrepreneurs who are focusing on their direct-sales careers.

SHRG’s high-performing independent sales force follows the company’s Blue Ocean selling strategy, an approach that encourages individuals to seek new markets, lead, and to “stop competing and start creating.” The Blue Ocean strategy is based on the book, “Blue Ocean Strategy,” written by Professor Renée Mauborgne, who notes that “the lesson here is that the best defense is offense, and the best offense… is to make a blue ocean shift and create your own blue ocean.”

Following this selling strategy, SHRG’s Elepreneurs are taught that, rather than competing directly in a competitive, direct-selling market, they should focus on making competitors irrelevant and succeeding in an uncontested marketplace.

In addition, SHRG’s Elepreneurs use the interactive, video-based VERB sales-marketing platform developed by Verb Technology Company Inc. The app utilizes proprietary interactive video data collection and analysis technology and provides next-generation customer relationship management, lead generation, and video marketing software applications.

Continued Momentum as Industry Leader

These selling strategies have resulted in sharp and consistent revenue gains. In the company’s 10-Q filed with the SEC for the three months ended Oct. 31, 2019, SHRG reported sales of $38.8 million for fiscal Q2 2019, an increase of 116% over sales of $17.9 million reported for the comparable quarter of 2018. Consolidated gross profit jumped by $16.2 million to $27.4 million for the same period compared to Q2 2018.

SHRG’s consolidated operating earnings were $3.9 million in the fiscal quarter ended Oct. 31, 2019, compared to $866,802 for the comparable period the prior year. Consolidated gross margin also grew 70.9% for the three months ended Oct. 31, 2019, compared to 62.2% the prior year.

These numbers are continuing a trend established over the past two years. In fiscal Q1 2019, SHRG achieved revenues of $35.4 million, more than double that of the comparable period in 2018. Even earlier, the company reported sales of $85.9 million for fiscal year ended April 30, 2019. This represents a nine-fold increase, or $77.5 million jump, over the company’s revenues of $8.4 million the prior year.

These numbers bring SHRG’s sales revenues since December 2017 — when the company’s Elevate product line was released — to an impressive cumulative total of $169 million.

Preparing for Success

SHRG is well prepared to continue and accommodate for this growth. The company recently expanded its corporate footprint by moving to a 10,000-square-foot facility in Plano, Texas, that offers ample room to expand as the company grows and flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

In addition, the company has a seasoned, expert leadership team in place, led by John “JT” Thatch. Thatch was appointed president and CEO of SHRG in March 2018, bringing to the company his expertise obtained from successfully starting, owning and operating several businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist SHRG as the company aims to expand and increase revenues.

Contact
469.304.9400 x 201
Info@SHRGinc.com
http://www.SHRGinc.com

Sharing Services Global Corporation (SHRG), closed Tuesday's trading session at $0.226, off by 9.5638%, on 85,907 volume with 36 trades. The average volume for the last 3 months is 140,469 and the stock's 52-week low/high is $0.0215/$0.280000001.

Recent News

chart

Bullfrog Gold Corp. (CSE: BFG) (OTCQB: BFGC) (FSE: 11B)

The QualityStocks Daily Newsletter would like to spotlight Bullfrog Gold Corp. (CSE: BFG) (OTCQB: BFGC) (FSE: 11B).

Bullfrog Gold Corp. (CSE: BFG) (OTCQB: BFGC) (FSE: 11B), on Monday summarized progress during the first half of 2020 and its exploration and development plans for the coming 12 months at the Bullfrog Project (“Project”) located 125 miles NW of Las Vegas, Nevada. Among highlights provided in the update, a key 2020 event was the C$2.0 million private placement completed in mid-January that funded Company and Project obligations while achieving main objectives and advancing the Project. To view the full press release, visit http://nnw.fm/PQEKi

Bullfrog Gold Corp. (the “Company”) (CSE: BFG) (OTCQB: BFGC) (FSE: 11B) is a Delaware corporation engaged in the acquisition, exploration and development of gold and silver properties in the United States. The Company controls strategic lands with established 43-101 compliant resources in one of the most exciting gold exploration areas in the United States. The Bullfrog Gold Project (“Project”) includes a lease/option on much of the lands where Barrick Bullfrog Inc., a subsidiary of Barrick Gold Corp., produced more than 2.3 million ounces of gold and 2.49 million ounces of silver from 1989 to 1999. The Project is located within the prolific Walker Trend about 125 miles northwest of Las Vegas, Nevada.

Project Highlights

  • The Company initially acquired 79 unpatented claims and two patents in mid-2011 and has since staked, leased, optioned, or purchased lands that now total 5,250 acres. Via a 2015 lease/option with Barrick, the Project includes the northern one-third of the Bullfrog deposit where most of the current resources in the Bullfrog mine area occur, along with their interest in the Montgomery-Shoshone deposit which gave the Company 100% control.
  • In mid-2017, a NI 43-101-compliant report by independent mining consultancy Tetra Tech Inc. estimated measured and indicated (“M&I”) resources of 624,000 ounces of gold and 1.73 million ounces of silver at average grades of 0.70 g/t and 1.93 g/t, respectively. The expansion plans of these two pits were based on a $1200 gold price, use of heap leach processing, and also included 110,000 ounces of inferred gold resources averaging 1.20 g/t. Barrick used conventional milling to process an average gold grade of 3 g/t.
  • The established resources and exploration potential of the Project are strongly supported by a large data base obtained from Barrick, including detailed information on 155 miles of drilling in 1,262 holes in the Bullfrog mine area.

Gold Rush in the Bullfrog Territory

The area around Beatty, Nevada has now attracted AngloGold Ashanti, Kinross Gold, Corvus Gold, Coeur Mining as well as the Company and Waterton. In this regard, Northern Empire Resources Corp’s property located a few miles east of the Project was acquired by Coeur Mining in October 2018 for C$117 million, implying a valuation of C$134/oz of inferred resources. As of today, the Company is trading at a significant discount to the valuation at which Northern Empire was purchased (http://nnw.fm/9NaaN), thereby highlighting the Company’s value proposition for investors.

Bullfrog Gold Corp. is focused on enhancing shareholder returns by concurrently advancing Project development and performing exploration drilling programs on several targets identified by the Company.

Secured Financing for 2020 Operations

Bullfrog Gold Corp. raised C$2 million in January 2020 through a private placement of shares priced at C$0.13/share plus a one-half warrant exercisable within two years at C$0.20 on a full warrant basis. The raise was carried out primarily to fund a drill program that started on May 1 (http://nnw.fm/6nZ0m), and was completed on June 6, 2020. Results from drilling 12,520 feet in 25 holes will be released in the coming weeks. The Company subsequently intends to conduct a preliminary financial analysis and complete further drill programs to advance the Project and add value. The financing was subscribed by several influential shareholders, including a former director of Northern Empire, who handled the sale of the company to Coeur Mining, and Eros Resources, the management of which has been involved with several high-profile mining projects and sales in the past.

Gold Prices estimated to average $1,800/oz in 2021

Gold prices have been on a remarkable run in 2020, rising by $245/oz to $1,760 prior to peaking in early May. Global central banks carried out 144 interest rate cuts thus far in 2020, reducing their rates by a cumulative 5,035 basis points (http://nnw.fm/jzZt0). Meanwhile, the IMF has estimated that global governments have introduced fiscal support measures amounting to over $9 trillion since the start of the COVID-19 pandemic (http://nnw.fm/Or9rI). The resulting weakness in the U.S. dollar and eventual inflationary pressures stemming from these measures prompted Credit Suisse to recently hike their gold price forecasts for the full year to $1,701/oz (from $1,570 previously), while the outlook for 2021 has been raised to $1,800/oz (versus $1,600 previously) (http://nnw.fm/Iqg0X).

Management Team

David Beling, CEO, President and Director
David Beling is a Registered Professional Mining Engineer with 55 years of diverse experience in areas such as engineering, development, permitting, construction, financing and management of mines and plants and the building and growth of several corporations. His initial employment included 14 years with Phelps Dodge, Union Oil, Fluor, United Technologies, and Westinghouse, followed by 41 years of senior management and consulting with 25+ U.S. and Canadian mining companies. In 2006-2007, he spearheaded an IPO, successfully drove equity raises totaling C$112 million and grew that Company’s market capitalization to $460 million. Beling has served on 14 boards since 1981, including three mining companies distinguished by the TSX Venture Exchange as top-10 performers.

Alan Lindsay, Chairman of the Board
Alan Lindsay is an entrepreneur and businessman who has founded seven companies within the mining and pharmaceutical industries, including Anatolia Minerals Development Ltd., Uranium Energy Corp., Oroperu Mineral, Strategic American Oil and AZCO Mining. Lindsay also developed the strategic vision for the 2011 acquisition and placement of the Project from NPX Metals into Bullfrog Gold Corp.

Kjeld Thygesen, Director
Kjeld is a graduate of the University of Natal in South Africa and has 48 years of experience as a resource analyst and fund manager. In 1972, he joined James Capel and Co. in London as part of its highly rated gold and mining research team before subsequently becoming manager of N. M. Rothschild & Sons’ commodities and Natural Resources Department in 1979. In 1987, he became an executive director of N. M. Rothschild International Asset Management Ltd., before co-founding Lion Resource Management Ltd., a specialist investment manager in the mining and natural resources sector, in 1989. Thygesen has been a director of Ivanhoe Mines Ltd. since 2001 and served as investment director for Resources Investment Trust PLC from 2002 to 2006.

Tyler Minnick, CFO and Director of Administration & Finance
A registered member of the Colorado Society of Certified Public Accountants with over 24 years of experience within the fields of accounting, auditing, and administrative services. Minnick has been engaged with the Company since mid-2011 and previously worked in the finance department of MDC Holdings/Richmond American Homes, one of the largest residential construction companies in the United States.

Bullfrog Gold Corp. (OTCQB: BFGC), closed Tuesday's trading session at $0.17865, off by 3.5628%, on 322,060 volume with 63 trades. The average volume for the last 3 months is 214,441 and the stock's 52-week low/high is $0.047449998/$0.209999993.

Recent News

chart

The Movie Studio Inc. (OTC: MVES)

The QualityStocks Daily Newsletter would like to spotlight The Movie Studio Inc. (OTC: MVES).

Though fads come and go, society’s obsession with film celebrity has never waned. Many a film fanatic admits to harboring fantasies of starring in movies, and one company is making that dream a reality as a component of its unique growth strategy. The Movie Studio (OTC: MVES) has devised a method by which to provide budding film stars and actors the unique opportunity to participate in the shooting of a movie through the submission of a virtual ‘audition’. Movie studios have historically sought to differentiate themselves through the cultivation of unique selling points – however, until recently, none have succeeded in making films a truly interactive experience for their viewers.

The Movie Studio Inc. (OTC: MVES) is a vertically integrated motion picture production company focused on acquiring, developing, producing and distributing independent motion picture content for worldwide consumption via subscription and advertiser video on demand (SVOD/AVOD), over the top (OTT) platforms, foreign sales and various media devices. The company is currently engaged in establishing its own OTT VOD platform to integrate both its own and aggregated feature film projects, television programming and other media intellectual properties. The Movie Studio is disrupting traditional media content delivery systems with its digital business model of motion picture distribution, and the company intends to create a direct server access platform of its content with geo-fractured territories for worldwide distribution.

The company has launched The Movie Studio App on Google Play and the App Store, enabling users to both view the company’s content and potentially become part of it. The app is in the completion stage, and The Movie Studio is conducting its final beta test of the app’s unique “audition submission” function, leveraging the company’s “Watch Our Movies, Be in Our Movies!” content platform and “Everyone’s a Star” campaign, which will be marketed via social media. Using the app, subscribers can upload a thumbnail photo of themselves along with a selfie video audition submission that showcases them reading character dialog. Audition submissions will then be reviewed by producers for possible participation of the auditionee in upcoming feature films.

The audition submission function provides the subscriber the ability to disrupt traditional motion picture casting and management, enabling access to participation in The Movie Studio’s independent motion picture and media content. At the same time, for the company this significantly reduces capital expenditures associated with those traditional media mechanisms. The Movie Studio’s unique business model capitalizes on the global demand for film content through the production and distribution of its own films while also providing opportunities for direct viewer involvement in its content.

The company operates using a growth-by-acquisition strategy that includes:

  • Purchasing legacy film libraries.
  • Upgrading acquired films to 4K resolution and remonetizing with “new” film content on popular VOD streaming platforms across the internet.
  • Strategic partnerships and media content alignment with other OTT platforms and cross-collateralization of leverageable media assets for worldwide distribution.
  • Producing micro-budget motion picture content with substantial production value utilizing new 4K technology and the company’s extensive legacy resources and unique production process, thereby significantly reducing capital expenditures while allowing for the potential of significant return on investment (ROI) with one successful production.
  • Controlling its revenue streams through server-driven geo-fracturing global territories and its own OTT platform.

Currently, The Movie Studio is producing three upcoming feature films: “Cause and Effect,” “The Last Warhead” and “PEGASUS” — all with completed electronic press kits and pitch decks and fully produced motion picture-quality trailers ready for talent, distribution and financial integration.

The company has been successful in producing, casting and distributing its films on major SVOD platforms without recognizable stars, which reduces capital expenditures. However, The Movie Studio intends to integrate recognizable stars into the productions at value propositions either pre- or post-completion of the intellectual property.

Through successful beta testing, The Movie Studio has monetized film assets on the Amazon, tubi tv, Comcast and Showtime platforms.

The company’s proposed server-based model will provide licensing payment from global territories without third-party distribution fees, which have traditionally been as high as 35%.

Founded in 1961 and formerly known as Destination Television, Inc., the company changed its name to The Movie Studio, Inc. in November 2012. The Movie Studio is headquartered in Fort Lauderdale, Florida.

Cord-Cutting Creates Opportunity for VOD Players

Consumers are no longer content waiting for their favorite programming to come on the air – they expect instant streaming access where and how they want it. This has led to increased “cord cutting,” with consumers severing ties with their traditional pay TV providers in favor of digital streaming services.

With the advent of smart TVs with app integration, consumers can now watch what they want to watch when they want to watch it, fracturing traditional cable bundling mechanisms.

With pay TV usage steadily declining – satellite and cable TV businesses in the United States lost approximately 6 million customers in 2019 alone – streaming platforms are poised to potentially replace traditional pay TV distribution models altogether. Approximately 12,000 U.S. consumers are cutting the cord every day.

As this shift in media delivery continues and as digital devices become more sophisticated and bandwidth increases, VOD platforms have the potential to scale significantly. The Hollywood “streaming wars” of recent years have created an environment in which smaller competitors, like The Movie Studio, are able to emerge as major brands.

The Movie Studio Inc. (OTC: MVES), closed Tuesday's trading session at $0.00905, off by 18.4685%, on 130,440 volume with 13 trades. The average volume for the last 3 months is 171,014 and the stock's 52-week low/high is $0.006099999/$0.064999997.

Recent News

chart

Wrap Technologies Inc. (NASDAQ: WRTC)

The QualityStocks Daily Newsletter would like to spotlight Wrap Technologies Inc. (NASDAQ: WRTC).

Wrap Technologies, Inc. (NASDAQ: WRTC) was highlighted in a publication today from FinancialNewsMedia.com, examining how, although the recent global health crisis has hampered the growth in the home security systems market, experts predict that stronger growth is on the horizon. A report from MarketsAndMarkets projects that, the global home security systems market size, which is valued at USD 53.6 billion in 2020, is expected to reach USD $78.9 billion by 2025, at a CAGR of 8.0% during the forecast period. The growth of the home security systems market is driven by factors such as growing awareness regarding home security systems, the emergence of the Internet of Things (IoT) and wireless technologies and increasing adoption of IP cameras for video surveillance amid COVID-19 crisis. 

Wrap Technologies Inc. (NASDAQ: WRTC) is an innovator of modern policing solutions. The company’s BolaWrap® product is a patented, hand-held remote restraint device that discharges an eight-foot bola style Kevlar® tether to restrain an individual at a range of 10-25 feet. Developed by award-winning inventor Elwood Norris, the company’s chief technology officer, the small-but-powerful BolaWrap assists law enforcement in safely and effectively controlling encounters, especially those involving an individual experiencing a mental crisis.

Non-Lethal Weapons Market Potential

The BolaWrap Remote Restraint device is an innovative police solution, designed to provide law enforcement with a unique mobile and humane restraint option that does not inflict pain and enables subjects to be detained from a distance without the use of force.

In 2015, the 10 cities with the largest police departments in the United States paid out a cumulative $248.7 million in settlements and court judgements in police misconduct cases, marking a 48% increase from the $168.3 million in 2010 (http://nnw.fm/ri0L9). The majority of these cases have centered around the improper use of force by law enforcement when subjugating individuals, with 25% of all fatal shootings by law enforcement in the United States reportedly involving mentally ill individuals who are often incapable of comprehending officer commands (http://nnw.fm/YVm8P). Moreover, the use of alternate devices has failed to produce the desired outcomes, with the use of tasers by police resulting in over 1,080 fatalities since 2000 (http://nnw.fm/2Nb1A).

This, in turn, has led to a greater demand for humane tools which are not reliant on pain compliance to subdue subjects. Since its IPO in December 2017, Wrap Technologies has enjoyed a spectacular rise in prominence. The company began field testing the BolaWrap product in July 2018, with the first international order received only a month later, in August 2018. By December 2018, the company had been uplisted to the Nasdaq Capital Market with over 1,000 shareholders – a significant increase from the 50 shareholders who had participated in the IPO just 12 months prior. Recently, the company has sought to increase its commerciality and product monetization, appointing Tom Smith, the founder of TASER International (now Axon, NASDAQ: AAXN), as its president in March 2019.

At present, over 140 police departments throughout the United States are actively carrying the BolaWrap, while over 1,700 police departments across the nation have reached out to the company to request BolaWrap demonstrations, training and quotes. BolaWrap has also been successfully marketed internationally and has been shipped to 19 countries thus far.

As of today, Wrap Technologies has built a network of 11 distributors across 45 states in the United States who are actively marketing the product to the over 900,000 active police officers in the country. In addition, the company now has a network of 15 international distributors based in 26 countries – with over 600 international requests received thus far for product demonstrations, training and quotes.

As a result and following the opening of its new 11,000-square-foot manufacturing facility in Tempe, Arizona, in October 2019, Wrap Technologies announced a 352% year-on-year increase in revenues for 3Q2019 – a testament to the growing popularity of its mobile restraint device.

The company expects its growth to continue as adoption rates of the BolaWrap product increase throughout the United States and globally. According to a study by Stratistics MRC, the addressable global market for non-lethal weapons accounted for $6.32 billion in 2016 and is set to rise to $11.85 billion by 2023.

Product Received to Positive Acclaim

  • “An innovation that is changing the world of policing.” – Chief Luther Reynolds, Charleston Police Department
  • “Anytime you can have a more humane response to someone in crisis, it’s not only good for the department, it’s good for society.” – Redditt Hudson, Regional Field Director of the NAACP (http://nnw.fm/1STXm)
  • “This is going to save lives.” – Chief Ed Hudak, Coral Gables Police Department
  • “I see this as one of the great tools if you encounter someone with a mental health crisis.” – Chief Steven Casstevens, Buffalo Grove Police Department

Recently completed $12.4 million financing round

Wrap Technologies announced that it had successfully completed its capital raising round on June 4, 2020, raising $12.4 million through a primary share placement priced at $6.00/share. The net proceeds will be use to further scale engineering, fund product development and provide working capital to meet worldwide demand for BolaWrap products and accessories (http://nnw.fm/byLV7). The company also announced that its founder, Elwood Norris, had chosen to exercise 100,000 outstanding warrants to contribute $500,000 to the capital raising efforts. Following the financing round, Wrap Technologies reported over $30 million in cash on hand.

Management Team

Elwood G. “Woody” Norris, Founder and Chief Technology Officer
Elwood G. “Woody” Norris is an award-winning American inventor and serial entrepreneur and currently serves as chief technology officer for Wrap Technologies Inc. Norris founded and served as a director and president of Parametric Sound Corporation (now Turtle Beach Corporation (NASDAQ:HEAR)) and also served as chief scientist at Turtle Beach. Norris previously founded LRAD Corporation (NASDAQ: LRAD) and, prior to retiring in 2010, was chairman of LRAD Corporation’s board of directors, serving as a technical advisor and product spokesperson. Norris has authored more than 80 U.S. patents, primarily in the fields of electrical and acoustical engineering, and has been a frequent speaker on innovation to corporations and government organizations. He is the inventor of Wrap Technologies’ patented and patent pending BolaWrap® technology.

Scot Cohen, Executive Chairman
Scot Cohen has more than 20 years of experience in institutional asset management, wealth management, and capital markets. Cohen founded and served as principal of the Iroquois Capital Opportunity Fund, a closed-end private equity fund which focused on investments in North American oil and gas. Cohen also co-founded Iroquois Capital, a New York-based hedge fund that managed approximately $300 million across its family of funds. Prior to Iroquois Capital, Cohen founded a merchant bank which actively participated in structured investments in public companies. Cohen is currently active on a number of public and private company boards and is involved with various charitable ventures.

David Norris, Chief Executive Officer
David Norris is an experienced executive who joined Wrap Technologies full-time in January 2018. From April 2014 to December 2017, he served in various executive roles, including president, at privately held loanDepot LLC as it rapidly expanded into the fifth largest mortgage lender in the U.S. loanDepot had 6,000 employees and generated $1 billion in revenue in 2017. Norris also served as CEO of Greenlight Financial, and president of LendingTree Loans. Norris’ career also includes executive and management roles at Toshiba America Information Systems and Qualcomm Personal. Earlier in his career, Norris served as a probation officer in San Diego for five years.

Tom Smith, President
Tom Smith co-founded TASER International (now Axon Enterprise Inc. (NASDAQ: AAXN)) (“TASER”) in 1993 and served as president of TASER until October 2006. He served as chairman of the board of directors of TASER from October 2006 until he retired to pursue entrepreneurial activities in February 2012. Amongst his most significant roles and responsibilities at TASER, Smith managed domestic and international sales, significantly expanding the sale and distribution of TASER’s products, including sales to more than 17,200 federal, state and local law enforcement agencies in over 100 countries. In 2012, he founded Achilles Technology Solutions LLC, which, through subsidiary ATS Armor, developed a line of ballistic solutions for law enforcement and military applications. Smith holds a B.S. in ecology and evolutionary biology from the University of Arizona and an M.B.A. from Northern Arizona University.

Jim Barnes, Chief Financial Officer
Jim Barnes has served as president of Sunrise Capital Inc., a private venture capital and financial and regulatory consulting firm, since 1984. Barnes was chief financial officer of Parametric Sound Corporation (now Turtle Beach Corporation), and also served as vice president administration at Turtle Beach Corporation. Since 1999, Barnes has been manager of Syzygy Licensing LLC, a private technology invention and licensing company he owns with Elwood Norris. Barnes previously practiced as a certified public accountant and management consultant with Ernst & Ernst and Touche Ross & Co., and as a principal in J. McDonald & Co. Ltd. in Phoenix, Arizona.

Wrap Technologies Inc. (NASDAQ: WRTC), closed Tuesday's trading session at $11.59, off by 2.1941%, on 825,599 volume with 5,301 trades. The average volume for the last 3 months is 1,493,649 and the stock's 52-week low/high is $3.06999993/$14.3999996.

Recent News

chart

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

Genprex Inc. (NASDAQ: GNPX) was featured today in a publication from BioMedWire, examining how modern-day mobile technology is making strides in the medical device industry and is opening up new avenues for both physicians and patients. However, for these devices to be successful, they need approval from the FDA. Initially, mobile technology was only referred to as the device that was implanted into patients and communicated directly to clinicians within the hospital’s confines.

Genprex Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.

Genprex Inc. (NASDAQ: GNPX), closed Tuesday's trading session at $3.67, off by 3.6745%, on 859,239 volume with 2,661 trades. The average volume for the last 3 months is 2,815,455 and the stock's 52-week low/high is $0.231000006/$7.0300002.

Recent News

chart

Siyata Mobile Inc. (TSX.V: SIM) (OTCQX: SYATF)

The QualityStocks Daily Newsletter would like to spotlight Siyata Mobile Inc. (SYATF).

Siyata Mobile Inc. (TSX-V:SIM / OTCQX:SYATF/ FRA: WK3D) is pleased to announce that it has completed a non-brokered private placement of 14,434,200 units (the “Units”) of the Company at a price of $0.10 per Unit for aggregate gross proceeds of $1,443,420 (the “Offering”). Each Unit consists of one common share of the Company (the “Shares”) and one-half of a common share purchase warrant, entitling the holder to acquire an additional common share of the Company at a price of $0.18 for a period of two years from the date of issuance (the “Warrants”).

Siyata Mobile Inc. (TSX.V: SIM) (OTCQX: SYATF) is a leading global developer and provider of Push-to-Talk Over Cellular ("PTT/PoC") systems for enterprise customers. The company specializes in connected vehicle products for professional fleets and markets its products under the Uniden® Cellular brand.

Since its inception in 2012, Siyata has amassed a customer base that includes cellular operators, commercial vehicle technology distributors, and fleets of all sizes in Canada, the U.S., Europe, Australia and the Middle East.

Recognized by the Toronto Venture Stock Exchange in 2018 as a Venture Top 50 Company, Siyata aims to deliver the highest quality and most technologically advanced mobile communication devices for global corporate workforces, fleets, homes and buildings.

The company has long been an industry pioneer, delivering the world's first 3G connected vehicle device as well as the world's first 4G/LTE vehicle mounted smartphone for First Responders and commercial fleets and vehicles.

Siyata is headquartered in Montréal, Québec, Canada.

Product Portfolio

Siyata's suite of technology includes numerous PTT and legacy devices, as well as cellular boosters designed to improve cellular signals in corporate warehouses, government embassies, retirement home campuses, banks and manufacturing plants.

The company's flagship product, the Uniden UV350, is the world's first vehicle-mounted 4G/LTE smartphone with crystal clear quality, carrier grade PTT, voice, text, video and data applications built into a single device. Specifically designed for First Responder and commercial fleet vehicles, the UV350 runs on cellular LTE networks that provide nationwide and global coverage, replacing traditional single purpose two-way radios that require a monthly fee and limited network coverage.

The Uniden UV350 is currently available through Bell Mobility, Canada's largest LTE network and PTT community. Expanding its availability, Siyata is completing network approval with two North American Tier 1 operators to launch the UV350 in the U.S. in 2019.

Management Team

CEO and Chairman Marc Seelenfreund is the founder of Siyata. He is also the founder of Siyata's parent company, Accel Telecom, an Israel-based company that specializes in importing and distributing innovative cellular and IP devices to fixed line operators and mobile providers within Israel. Prior to establishing Accel, Seelenfreund was a vice president at Sunrise Corporation in New York where he focused on financing publicly traded technology companies. Seelenfreund has a law degree from Bar Ilan University, is a board member at Israel's leading private university, and has served as an officer in the Israel Defense Forces.

Glenn Kennedy, vice president of sales, has over 25 years of sales experience in the telecommunications industry. Prior to joining Siyata in 2016, Kennedy managed sales nationally for Motorola Canada, HTC Communications Canada, and Sonim Technologies. He holds a bachelor's degree in honors business administration from the Richard Ivey School of Business at the University of Western Ontario.

CFO Gerald Bernstein, a professional chartered accountant, has spent 20 years focusing on private equity financing and tax efficient corporate structuring in multi-jurisdictional arenas. He holds a bachelor's degree of commerce as well as a graduate diploma in public accountancy from McGill University. Bernstein has been a member of the Canadian Institute of Chartered Accountants since 1987.

Gidi Bracha, Vice President of Technology, has served in this position since 2011 and spearheaded the development of both the Truckfone, Voyager and UV350. Bracha served in various key positions at Cellcom, Israel's leading cellular provider, including head of car mobility products and director of type approvals. Bracha served as an engineer technician in the Anti-Aircraft division of the Air Force in the Israel Defense Forces and holds a bachelor's degree in engineering and business management from the University of Derby.

Siyata Mobile Inc. (SYATF), closed Tuesday's trading session at $0.0748, off by 6.2657%, on 11,140 volume with 4 trades. The average volume for the last 3 months is 238,857 and the stock's 52-week low/high is $0.061999998/$0.370900005.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.